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ABSTRACT
Antimicrobial peptides are important components of the innate immune systems ability
to fight disease. They display widespread distribution throughout the animal and plant
kingdom and directly inhibit infection rapidly. In numerous cases these peptides provide
additional roles acting upon the immune system to co-ordinate a protective response.
The defensins, one of the largest antimicrobial peptide families, can be subclassed into
the a, j8 and 9 defensins based on their six cysteine spacing and connectivity. The (3-
defensins which are expressed at a variety of epithelial surfaces, display antimicrobial
properties and play important roles in host defence.
The aim of this project was 1) to evaluate the antimicrobial and chemoattractant
properties of a novel five cysteine defensin related peptide (Defrl), 2) to analyse
Defbl4, the murine orthologue of human beta defensin 3 and 3) to investigate the
properties of defensin inspired peptides.
This thesis describes the antimicrobial and chemoattractant properties of Defrl. This
work suggests that Defrl displayed antimicrobial activity against a panel of organisms
for which antimicrobial treatment is limited or non-existent. In addition Defrl displayed
potent chemoattractant properties regarding various immune cell types and is the first
example of a /3-defensin that does not act through CCR6.
Data presented in this thesis describes the first study of the murine peptide Defbl4. This
concluded that a synthetic preparation of Defbl4 displayed potent antimicrobial activity
and roles within immune cell migration.
In this thesis, various defensin inspired peptides were subjected to study. Defbl4 was
used as a template for functional analysis and concluded that smaller N-terminal
peptides displayed potent antimicrobial activity. Interestingly chemotactic activity was
absent and toxicity remained similar to that of the original Defbl4. These studies have





1.1 Requirement for novel antimicrobials
Since the discovery of penicillin, the management and eradication of bacterial
infections has been revolutionised. The identification and development of the first
lifesaving antimicrobial has encouraged further drug design to help combat a spectrum
of micro-organisms. Currently an impressive range of antimicrobial agents are
available providing treatment against an array of organisms. Unfortunately the end of
the antimicrobial era is upon us with the decline in efficacy becoming a common
occurrence. The misuse of these agents has resulted in a prevalence of multiple drug
resistant organisms within the population.
The need for antimicrobial agents is frequently stated, with an increase in
hospital acquired infections and highly resistant organisms, problems with unsuccessful
treatment are common. New effective antimicrobial agents are not emerging to meet the
demand as frequent as they did in the past. Pharmaceutical companies are reluctant to
participate in the research and development of anti-infective agents. Within the past ten
years the number of anti-infective programmes within large pharmaceutical companies
has declined dramatically. Key players in drug discovery are abandoning the field in
favour of long term chronic illnesses. These ailments require continued drug therapy
and therefore a continued income for the company. The majority of antimicrobials
prescribed cure the infection and the demand for long term therapy is minimal. Despite
this the global market for antibiotics in 2002 was in the region of US $ 25 billion
(Coates et al., 2002). Although finance is a huge implication in development the task
of developing novel antimicrobials is vast. New classes are required with novel targets
and mechanisms. The antimicrobial pipeline is empty as the source of targets is small
and very limited. In addition the cost of research for potential agents is not worth
forsaking for the limited financial gain.
1.2 Antimicrobial peptides
Antimicrobial peptides are important components of the innate immune response
common to invertebrates, vertebrates and plants. Throughout evolution these peptides
have retained their antimicrobial potency and are thought to have arisen from multiple,
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independent sources, possibly through convergent evolution (Zasloff et al 2002). These
small diverse peptides provide a rapid first line of response against infection and are
generally less than 10 kDa in size, contain 12-60 amino acids and have a cationic
nature.
The majority of peptides can be grouped into three structural classes (Yount et
al., 2006), linear peptides often of ct-helical tendancy, cysteine stabilised peptides
mostly conforming to a /3-sheet structure and those with one or more predominant
amino acid residues, but variable in structure. The linear non- cysteine peptides such as
magainin and cecropin are found within the skin secretions of amphibians and in insects
respectively. While many of these peptides exist as extended or unstructured in
aqueous solution, they have the ability to assume the a-helical structure within the
membrane. The cysteine containing /3-sheet peptides are the most prominent class of
the antimicrobial peptides and consist of defensins and protegrins. These peptides are
frequently comprised of several anti-parallel /3-strands, stabilised by disulfide bonds
which occasionally contain an a-helix. A common motif was discovered through
proteomic analysis (Yount et al., 2004) and termed the y-core. This is composed of two
anti-parallel /3-sheets, with basic residues polarised along its axis. This structural motif
is presenting all the major classes of cysteine stabilised host defense peptides. There
are many examples of antimicrobial peptides in which one or more amino acid residues
are dominant. For example, histatins contain predominant histidine residues and
indolicidin contains increasing amounts of tryptophan.
Antimicrobial peptides are ideal candidates for potential theraputics in the field
of anti-infectives. Considerable commercial and academic research has focused on
developing a new generation of antimicrobial agents based on these natural antibiotics
(Hancock et al., 2002). Numerous companies have been established from antimicrobial
peptides, Helix Biomedix, Novazymes, Novabiotics, Intrabiotics and Micrologix
Biotech Inc with all having lead peptides in research programmes and in clinical trials.
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1.3 The defensin family
The defensins are diverse members of a large family of antimicrobial peptides,
widely distributed in plants, mammals and insects. These cysteine-rich peptides vary in
their length, the spacing of their cysteine residues and their disulfide connectivities.
The defensins are generally small (3-6kDa), cationic peptides and were originally
isolated from rabbit neutrophil granules (Selsted et al., 1985).
1.3.1 Classification of the defensins
The classification of defensins is based on the spacing and arrangement of their
disulfide bridges (Figure 1.1) that stabilise the /3-sheet structure. Mammalian defensins
can be classified into three subfamilies; the originally isolated a-defensin (also termed
classical defensins), the /3-defensins and the more recently identified 0-defensins (Tang
et al., 1999). Insect and vertebrate defensins all contain six residues with variations in
the spacing of the cysteine residues and their disulfide connectivities (reviewed in Yang
et al., 2001). Regarding insect defensins the cysteine residues are connected C1-C4,
C2-C5 and C3- C6. The connectivities of the odefensins are C1-C6, C2-C4 and C3-C5
and the /3-defensins are reported to have C1-C5, C2-C4 and C3-C6. The #-defensins
(with the rhesus 0-defensin 1) display the C1-C6, C2-C5 and C3-C6 connectivities.
Defensins are also found in some plant species (reviewed in Broekaert et al., 1995) but
these display eight cysteine residues and are linked C1-C8, C2-C5, C3-C6 and C4-C7.
1.3.2 The mammalian defensin subfamilies
The mammalian defensin gene family are present at five syntenic loci in mouse
and human genomes with the main locus on human chromosome 8p22-23 and mouse
chromosome 8A3 (Schutte et al., 2002). The different subfamilies of defensins are
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1.3.2.1 The ce-defensin subfamily
The a-defensins were initially identified in the granules of both rabbit and
human neutrophils (Selsted et ah, 1985; Ganz et ah, 1985). These defensins (HNP-1-4)
are abundant in granules of polymorphonuclear leukocytes (PMN) or expressed by
paneth cells within the human gut (HD-5, HD-6) (Selsted et al., 1992). Mouse
neutrophils do not express detectable amounts of odefensins (Eisenhauer et ah, 1992)
but they do express many enteric odefensin peptides known as cryptidins in intestinal
paneth cells (Ganz et ah, 2003). The a-defensins are encoded by genes comprising
three exons and are initially synthesised as prepropeptides (Lehrer et ah, 1993). The
prepropeptides contain an endoplasmic reticulum signal sequence of approximately 20
residues, a 45 amino acid residue anionic propiece and a mature cationic peptide of
around 30 residues. The signal sequence is cotranslationally removed from its amino
terminus and the mature peptide is generated. Cleavage of the propiece has been shown
to be required before antimicrobial activity can be observed (Valore et ah, 1996). The
HNPs are synthesised by promyelocytes and the mature peptides are stored in the
primary granules of neutrophils (Ganz et ah, 2003). Unlike the human neutrophil
peptides, HD-5 is released as a propeptide and is processed extracellularly and is
mediated with trypsin (Ghosh et ah, 2002). Regarding the mouse cryptidins, cleavage
of the propiece occurs extracellularly and is mediated using matrilysin (Wilson et ah,
1999)
The human neutrophil peptides predominantly have a /3-sheet structure stabilised
by the presence of their three disulfide bonds. NMR studies have been performed on
various human neutrophil peptides. HNP-3 has been crystallised to 1.9 A resolution
(Hill et ah, 1991) revealing a dimeric structure.
The mature a-defensins have been shown to possess broad spectrum
antimicrobial activity against both Gram positive and negative organisms. S. aureus,
P. aeruginosa, E. coli, C. neoformans have exhibited varying antimicrobial action
(Miyasaki et ah, 1990). HNP-1 and HNP-2 have shown activity with C. albicans
(Lehrer et al., 1988) but HNP-3 was inactive. The antimicrobial activity has also been
shown to diminish in the presence of a high salt environment (Lehrer et ah, 1988). Not
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only do the odefensins display antimicrobial activity, evidence has emerged that they
have potent antiviral activity (Daher et al., 1986). Herpes simplex virus,
cytomegalovirus, influenza and HIV have been shown to be inhibited (Klotman et al.,
2006)
Human neutrophil peptides have been shown to possess an array of additional
activities (Yang et al., 2001). The a-defensins from humans, rabbits and guinea pigs
have been shown to induce histamine release and peritoneal mast cell degranulation
(Befus et al., 1999). Human odefensins have been shown to interact with complement,
binding to Clq (Panyutich et al., 1994). Chemotaxis has been observed with the
migration of immature dendritic cells and naive T-cells (Yang et al., 2000).
1.3.2.2 The 0-defensin subfamily
The 0-defensins are the most recent defensin family to be identified from Rhesus
macaque leukocytes. Rhesus theta defensin-1 (RTD-1) is formed from two different ce¬
de fen sin precursors involving the head to tail ligation and the formation of two new
peptide bonds (Tang et al., 1999). RTDla and RTDlb are translated, their ends are
spliced and both are ligated together producing a circular defensin (Figure 1.2). The
cyclic peptide contains 18 residues and forms 3 disulfide bonds. Two homodimeric d-
defensins (Tran et al., 2002) RTD-2 and RTD-3 are predicted splicing products ofRTD¬
la and RTDlb and were purified from rhesus monkey bone marrow. Genes encoding
functional peptides have only been found in Rhesus monkeys. Human bone marrow
expresses a pseudogene that encodes antimicrobial peptide homologoues to the circular
rhesus monkey mini-defensins (0-defensins) termed retrocyclin (Cole et al., 2002).
Retrocyclin was made synthetically and was shown to protect human CD4+ cells from
infection by HIV-1 in vitro, was noncytotoxic and demonstrated effective killing against
certain organisms. In the human genome at least six genes for coding the 6-
defensins have been found. Premature stop codons in the genes abort translation and




Figure1.2PosttranslationalprocessingfRTD-1e ur ors AdaptedfromT nget\.,1999 Smallarrowsindic tewherRTDlandbrsplic d,ge atingt nonapep idesh nlig tproduc circularmat reRTD1
1.3.2.3 The /3-defensin subfamily
The /3-defensins are produced by vertebrates including mammals and birds. The
first /3-defensin reported was isolated from the tongue of a cow and termed tracheal
antimicrobial peptide (Diamond et al., 1992). /3-defensins were subsequently found in
bovine granulocytes (bovine neutrophil /3-defensins, BNBD1-13 (Selsted et al., 1993)),
and in chicken leucocytes (gallinacin, Gal-Ice and Gal 1-2 (Harwig et al., 1994)). The
spacing and connectivity of the cysteine residues (C1-C5, C2-C4 and C3-C6) differed
from those observed with that of the ce-defensins (C1-C6, C2-C4 and C3-C5).
1.4 Human /3-defensins
Numerous human /3-defensin genes exist but four human /3-defensins have been
described in great detail (HBD1-4) although at least 28 more have been reported
(Schutte et al., 2002). Human /3-defensin 1 was the first human defensin identified and
purified from the plasma of renal patients (Bensch et al., 1995). Human /3-defensin 2
was originally isolated from psoriatic skin lesions (Harder et al., 1997) similar to human
/3-defensin 3 which was purified from psoriatic scales (Harder et al., 2001). Human (3-
defensin 4 was originally reported through genomic analysis (Garcia et al., 2001a).
HBD1 was identified from human blood filtrate as a 36 amino acid mature
peptide with sequence homology to that of the bovine defensins (Bensch et al., 1995).
HBD1 is constitutively expressed in a variety of tissues including the pancreas and
kidney with lower levels detected in the salivary glands, testis, thymus, placenta and
small intestine (Zhao et al., 1996). HBD1 expression was also detected in the collecting
ducts and the loops ofHenle (Schnapp et al., 1998). The HBD1 gene (DEFB1) spans a
7 kb region with an intron of 6962 bp separating two exons (Liu et al., 1997). HBD1 is
not inducucible by inflammatory stimuli of bacterial products including
lipopolysaccharide (LPS), interleukin 6 (IL-6), Interferon- 7 (IFN-7), phorbol myristate
aetate (PMA) or tumor necrosis factor- a (TNF-o;) (Zhao et al., 1996). The promoter
region does not contain the necessary transcription factor binding sites required to
respond to these factors.
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HBD2 was isolated from lesional psoriatic scale extracts as a 41 residue peptide
(Harder et al.,\991). Human /3-defensin 2 is the first member of the family found to be
an inducible peptide. Expression of this peptide has been detected in the skin, lung,
trachea, urogenital tract, salivary gland and uterus (Harder et al., 1997; Bals et al.,
1998a; Hiratsuka et al., 1998). HBD2 is induced in response to microbial and host
factors due to the presence of one or more multiple nuclear factor kappa B (NF-/cB)
consensus binding sites. The flanking region contains four NF-kB sites that are not
evident in DEFB1 gene but are in TAP, which is also upregulated by inflammatory
stimuli (Russell et al., 1996). Recognition of bacterial products and proinflammatory
cytokines resulted in NF-/cB activation and transcription ofHBD-2 (Becker et al., 2000;
Diamond et al., 2000). HBD2 expression has also been shown to be mediated by Toll
Tike Receptor -2 (TER2) (Birchler et al., 2001). The peptide has also been shown to act
like an endogenous ligand for TFR 4 on immature dendritic cells and induced dendritic
cell maturation (Biragyn et al., 2002).
The third human defensin to be identified was human /3-defensin 3 (HBD3) and
similar to HBD2 this was purified from psoriatic skin lesions (Harder et al., 2001).
The search for the third defensin was driven by the fact that the previous peptides could
not kill gram positive organisms within lesional keratinocytes. It was hypothesised that
additional peptides must be present displaying activity against S. aureus. HBD3 can be
found to contain 45 amino acid residues and is expressed skin, tonsils, gingival
keratinocytes, skeletal muscle, adult heart, testis and esophagus (Harder et al., 2001)
and can kill S. aureus.
The fourth peptide to be identified was human /3-defensin 4 and this was
detected by genomic analysis (Garcia et al., 2001a). HBD4 transcripts were detected in
the testis at high levels while lower levels were present in the kidney, lungs, thyroid,
stomach and uterus. The expression ofHBD4 was found to be upregulated by exposure
to bacteria and also to phorbol-12-myristate-13-acetate (PMA). Analysis of the
flanking region displayed the presence of several AP-1 sites and GATA1 binding sites
but no NF-/cB or STAT binding sites (Garcia et al., 2001b). HBD4 has been shown to
be induced in primary respiratory epithelial cells by phorbol ester or P. aeruginosa or
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S. pneumoniae. IL-lo; IL-6, IFN-7 and TNF-a do not induce HBD4 (Garcia et al.,
2001b).
1.5 Murine /3-defensins
The first murine /3-defensin to be identified, Defbl (mBD-1) was found based on
the homology of the human /3-defensin 1 (Huttner et al., 1997; Morrison et al., 1998).
The Defbl gene contains two exons, the first encoding the signal sequence and part of
the proregion, whereas the second exon encodes the remainder of the propiece and the
mature peptide. Defbl has been detected at high levels in the kidney, and also found at
lower levels in the heart, lungs, gut and skeletal muscle. Defbl has demonstrated salt
sensitive antimicrobial activity against E .coli, P. aeruginosa and S. aureus (Morrison et
al., 1998; Bals et al., 1998b). However when tested against B. cenocepacia (Morrison
et al., 1998) the peptide failed to display antimicrobial activity. Mouse models deficient
in Defbl displayed higher numbers of S. aureus in the bladder (Morrison et al., 2002a;
Moser et al., 2002).
The second murine /3-defensin Defb2 has also been reported (Morrison et al.,
1999). Defb2 gene encodes a 71 amino acid peptide. The expression of Defb2 was
detected in the lungs, skin, kidney, uterus and trachea and was found to be induced
following treatment with lipopolysaccharide (LPS) unlike that of Defbl. Defb2 has
been shown to bind to CCR6 and chemoattract immature dendritic cells but not mature
dendritic cells (Biragyn et al., 2001).
The murine /3-defensin 3 was isolated from lungs using primer sequences based
on a rat /3-defensin (Bals et al., 1999). Further analysis of the gene revealed the
presence of a NF-/cB site in the promoter region of the gene and a 1.7 kb intron
separating two exons. Defb3 also contains an additional amino acid residue between
the second and third cysteine residues and displays expression in the salivary glands,
epididymis, liver, brain, ovaries and lung. Within the liver the expression was induced
following exposure to P.aeruginosa via airway instillations.
Murine /3-defensin 4 has also been reported (Jia et al., 2000) with expression
being detected in the oesophagus, trachea and tongue but not induced via inflammatory
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stimuli. The gene comprises of two exons separated by an intron of 2.4 kb. Functional
analysis data on this peptide has not been published.
1.6 Evolution of the defensins
The defensin subfamilies share common characteristics from their cationic
properties, small size and cysteine residues. Structural and functional similarities
suggest a common ancestor. Based on these observations it has been proposed that they
possibly descended from a common ancestral gene by duplication and divergence
(Hughes et al., 1999). However it is difficult to determine whether the mammalian a-
defensins, the vertebrate /3-defensins and the insect defensins are homologous or have
independently evolved. The spacing of the cysteine residues in the disulfide bonds and
the three dimensional structure are evidence for a distant relationship. Nucleotide
substitutions in recently duplicated mammalian defensin genes show that the rate of
nonsynonymous substitution exceeds that of the synonymous substitution in the region
of the gene encoding the mature peptide. This is evidence of positive selection driving
the diversification of the defensins. The 8p22-p23 locus has evolved by successive
rounds of duplication followed by substantial divergence involving positive selection
(Semple et al., 2003). Positive selection, disproportionately favours alterations in the
charge of the amino acids and has been implicated as driving second exon divergence in
these genes (Semple et al., 2003).
1.7 Structure of the /3-defensins
The structures of HBD1, HBD2 and HBD3 (Hoover et al., 2000; Harder et al.,
2001; Schibli et al., 2002) have been determined (Figure 1.3). Mouse /3-defensin 7 and
8 have also been reported (Bauer et al., 2001). The tertiary structures of these defensins
are similar despite the differences in their amino acid sequences. The defensins consists
of three /3-strands arranged in an antiparallel sheet and held together by three
intramolecular disulfide bonds. The /3-sheet is flanked by an a-helical segment formed
by the N-terminal fragment of the molecule (Pazgier et al., 2006) although this is not
present in the a-defensins and bovine /3-defensins (Hill et al., 1991). This a-helix
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Equivalent orientation 180°
Figure 1.3 Structural comparisons ofhuman 6-defensin 1, 2 & 3
Schematic representation ofHBD1, 2 and 3 displaying an N-terminal a-helix, 3 (3-
strands arranged in an antiparallel sheet and held together by three intramolecular
disulfide bonds. The positively and negatively charged areas of the solvent-accesible
surfaces are coloured in blue and red respectively. Figures were taken from Pazgier et
ai, 2006, constructed using MOLMOL and Grasp.
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orientation is stabilised by the disulfide bond (C1-C5) to the /3-sheet. A conserved
motif Gly-X-Cys is found in the second /3-strand and forms a /3-bulge (Hoover el al.,
2000). The /3-bulge is thought to be responsible for a twist in the /3-sheets and is
necessary for the formation of the structure and the correct folding (Xie et al., 2005).
The residues forming the /3-sheet have been shown to be less susceptible to negative or
positive selection during the evolution of the mammalian /3-defensin genes (Semple et
al., 2003).
1.8 Function of the /3-defensins
The /3-defensins display a diverse array of biological activities and possibly the
most recognised is their ability to act as antimicrobials. Additional roles highlight their
potential as immunomodulators indicating their potential roles in regulating both the
innate and adaptive immune responses.
1.8.1 Antimicrobial action
The /3-defensins have been branded initially as antimicrobial peptides and
numerous studies have focused on these properties. The /3-defensins have the capacity
to kill or inhibit in vitro a wide variety of bacteria and fungi particularly at low
concentrations of salt and plasma proteins (Selsted et al., 1993; Ganz et al., 1998).
HBD1 and HBD2 have displayed effective antimicrobial properties against Gram-
negative organisms but appear to be less potent against Gram positive organisms.
HBD3 displays potent broad spectrum activity against both Gram positive and negative
organisms (Goldman et al., 1997; Bals et al., 1999). The activity of the /3-defensins has
been shown to be inhibited by the presence of divalent cations (Tomita et al., 2000) and
sodium chloride (Garcia et al., 2001b).
The physicochemical properties of the /3-defensins determine their antimicrobial
activity and their specificity. The balance of net positive charge, the hydrophobic
residues and the amphiphilic character determine the activity. All /3-defensins share a
very similar structural core, consisting of three /3-strands arranged in an antiparallel
sheet and held together by three intramolecular disulfide bonds. Microbial specificity
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has been suggested to result from variable arrangements of the non-conserved residues
(Semple et al., 2003; Sahl et al., 2005).
Knockout studies have provided some interesting results. Knockouts of a single
defensin, mouse /3-defensin-1, results in a delayed clearance of Haemophilus influenzae
from the lung (Moser et al., 2002) and increases colonization by Staphylococcus species
in the bladder (Morrison et al., 2002a).
1.8.1.1 Mechanism of action
Numerous studies have focused on the mechanisms responsible for
antimicrobial action of the /3-defensins and are as yet, not clear. The role of interactions
has been extensively studied between negatively charged membranes and cationic
peptides using artificial membranes (Bohling et al., 2006; Wimley et al., 1994). The
defensins have been described as being membrane acting agents (Hancock et al., 1998)
targeting the cell membrane which also forms the basis of their selectivity. The
positively charged peptides interact with the negatively charged structures of the
microbial membranes. These components include teichoic acid in the Gram positive
organisms and lipopolysaccharide in the Gram negative organisms. These structures are
specific to prokaryotic cells and not found in eukaryotic cells therefore providing
specificity for the prokaryotic membrane. In addition the membranes of the eukaryotic
cells contain cholesterol and zwitterionic phospholipids that display no overall charge,
althought the inner leaf display negatively charged properties.
The molecular details of the interactions between the /3-defensins and the
membranes are not clearly understood. Different models have been proposed and the
precise mechanism remains to be investigated.
The initial attraction between the target cell and the peptide is electrostatic
involving the positively charged peptide and the negatively charged cell membrane.
The importance of this reaction has been confirmed experimentally for several of the a-
defensins (Satchell et al., 2003). Regarding Gram negative organisms, the peptides
must cross the outer membrane first. Gram negative organisms consist of two cell
envelope membranes, a cytoplasmic membrane and an outer membrane, separated by
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periplasm containing a thin layer of peptidoglycan. The initial uptake within the Gram
negative organisms is proposed to utilize the self-promoted uptake pathway (Hancock et
al., 2000). This mechanism was first proposed to explain the uptake of polycationic
antimicrobials such as the aminoglycosides and polymyxins (Sawyer et al., 1988). The
peptides interact with the polyanionic surface of the membrane and have an affinity for
LPS where they competitively displace the divalent cations Ca2+ and Mg2+. The
peptides disrupt the outer membrane, which in turn allows the uptake of the peptides
into the periplasmic space (Hancock et al., 1988).
Two different models have been proposed to describe the structure of the
peptide membrane pore (Ganz., 1999). According to one model, the barrel stave model
(Figure 1.4), the /3-defensins might form channel-like pores spanning across the
membranes. The peptides oligomerise like the staves of the barrel with the complex
behaving like a transmembrane protein. This has been shown to be initiated with the
peptide alamethicin (Brogden et al., 2005) whereby the hydrophobic regions align with
the lipid core region of the bilayer and the hydrophilic peptide regions form the interior
region of the pore.
The second model, the carpet model (Figure 1.5), peptides accumulate on the
surface bilayer. Peptides are electrostatically attracted to the phopholipid head groups
at numerous sites covering the surface like a carpet. This neutralises the negatively
charged lipids and the integrity of the bilayer is disrupted allowing passage of ions and
larger molecules. This mechanism has been explained for ovispirin (Brogden et al.,
2005) which orientate parallel to the membrane surface.
Both the barrel stave model and the carpet theory have their advantages and
disadvantages. The /3-defensins ability to oligomerise and display an amphiphilic
character (Pazgier et al., 2006)) supports the barrel stave model although specific
oligomerisation is required for forming the channel and this has not been directly
observed with the defensins. According to the carpet model, this does not require
extensive hydrophobicity or specific oligomerization. The hydrophobic regions of the
peptides play a role in the stabilisation of the oligomeric structure and the charge
dependant activity of these peptides agrees with the electrostatic interactions required
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Figure 1.4 The barrel-stave model of antimicrobial peptide induced killing
The attached peptides aggregate and insert into the membrane bilayer so that the
hydrophobic peptide regions align with the lipid core region and the hydrophilic peptide
regions form the interior region of the pore. Hydrophilic regions of the peptide are
coloured red and hydrophobic regions blue.
Figure taken from Brogden et al., 2005
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Figure 1.5 The carpet model of antimicrobial peptide induced killing
In this model the peptides orientate parallel to the surface of the lipid bilayer and
forming an extensive layer or carpet. Hydrophilic regions are coloures red and
hydrophobic regions of the peptide are coloured blue.
Figure taken from Brogden et al., 2005
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for the carpet model. Both the barrel stave model and the carpet model do not describe
the full picture required for peptide membrane interaction. Further investigation is
required to elucidate the mechanisms and the components involved in the killing.
How the peptide actually kills the target cell is subject to much debate. One
theory suggests that the formation of channels in the cytoplasm results in loss of cell
viability therefore being responsible for death (Falla et al., 1996). Another theory
implies that antimicrobial peptides enter the cell through the disrupted membranes and
interact with intracellular targets (Hancock et al., 1997; Brogden et al., 2005).
1.8.1.2 Resistance mechanisms to antimicrobial peptides
Some species of bacteria have developed mechanisms to alter the structures
involved in the interactions with cationic antimicrobial peptides. By altering these
points the interaction with cationic antimicrobial peptides is diminished and
subsequently the peptides become ineffective at killing. (Peschel et al., 2001).
Numerous organisms have developed resistance mechanism in hope of encouraging an
established persistent infection. Mechanisms of resistance include membrane bound
proteases, efflux pumps and modulation of outer membrane permeability through
various structural modifications (Tzeng et al., 2005)
The cystic fibrosis lung pathogen, Burkholderia cenocepacia is highly resistant
to the action of antimicrobial peptides (Hancock et al., 1997). Antimicrobial peptides
like polymyxin have an inability to disrupt and permeabilise the outer membrane
possibly connected to the external structures of LPS. Burkholderia LPS contain one
third of the phosphate content present in the species Pseudomonas therefore limiting the
potential cationic binding sites (Moore et al., 1986). Recently it has been demonstrated
that B. cenocepacia has to possess the complete core oligosaccharide attached to lipid A
for it to maintain its resistance to antimicrobial peptides (Loutet et al., 2006) (Figure
1.6). Furthermore, the LPS of Burkholderia has a change in the inner core. The Ko
residue in the Ko-ce(2-4)-Kdo disaccharide is substituted with Ara4N at position 8
(Gronow et al., 2003) although this isolate ATCC 25416 belongs to genomovar I which









Figure 1.6 Burkholderia LPS Schematic
Structure ofBurkholderia cepacia complex lipopolysaccharide (adapted from
Mahenthiralingam et al 2005) displaying lipid A composed of
with fatty acid side chains and phosphodiester-linked 4-amino-4-deoyarabinose. The
inner core polysaccharide consists of 3-deoxy-D-manno-oct-2-ulosonic acid (KDO)
which is attached to lipid A and D-glycero-D-talo-oct-2-ulosonic acid (KO). In addition
heptose moieties with sugars complete the inner core. Attached to the inner core are
various hexose sugars which form the outer core region. The O-antigen is a repeating
unit (n) of specific sugar residues that form the basis of serotyping.
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Staphylococcus aureus has been reported to be resistant to a variety of
antimicrobial peptides (Peschel et al., 1999). The mprF gene of S. aureus determines
resistance (Peschel et al., 2001). S.aureus achieves resistance to cationic antimicrobial
peptides by modifying anionic phosphatidylglycerol with L-lysine resulting in a
repulsion of the positively charged peptides (Staubitz et al., 2004).
1.8.2 Chemotaxis
Chemotaxis is defined as a process of direct migraton of cells along a chemical
gradient. Within the immune system chemotaxis maintains a huge role in play with
large numbers of immune related cells locating to sites of inflammation and infection.
Many immune related cells possess the ability for chemotaxis (Luster et al., 2002). A
large number of chemoattractant substances have been identified, such as the
chemokines. Chemokines are low molecular weight chemoattractants activating and
inducing a variety of cell types (Murdoch et al., 2000)
Many immune cells patrol throughout the body and migrate to a specific point
following a chemotactic gradient (Delves et al., 2000). Using selectin molecules
expressed on the surface of neutrophils and T-cells, inflammatory signals upregulate
adhesion molecules such as Sialyl-Lewisx on the surface of the vascular endothelium
adjacent to the site of infection. The L-selectins on the immune cell surface interact
with the adhesion molecules allowing the patrolling cell to bind to the endothelium
adjacent to the site of infection. The immune cell sheds the L-selectin, integrins are
activated and on the endothelium cells up regulate the E-selectins. The integrin
interaction with the E-selectin arrest the rolling cell and allows firm adhesion to the
endothelial surface. The immune cell then passes through the endothelial wall, moving
up the chemotactic gradient towards the site where it is required.
Various chemokines attract the immune cell through the endothelium. These
chemokines are immobilised on the endothelial surface via presentation molecules such
as proteoglycan and also due to the production of chemokines by the endothelial cells
themselves (Witko-Sarset et al., 2000). The cell is suggested to be pulled through the
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endothelium by the interaction of the immune cells integrins and the P-selectins
concentrated on the endothelial cells (Burns et al., 2000). The ability of the leuckocytes
to navigate throughout the gradients of chemoattractants has been suggested by
responding to one agonist source then another. The initial direction of the cell is
dictated by the closest steepest chemoattractant gradient. This is then regulated by
desensitisation of receptors, attraction by distant agonists and then end-target attractants
such as formyl peptides and C5a. The chemotactic cells are elongated in shape and
thought to be more sensitive at one end to an attractant. G-protein coupled receptors
detect chemokines (Ijima et al., 2002). The mechanism by which the cell senses the
direction of the gradient remains unknown however it is proposed that the balance
between the rapid excitatory and the slower inhibitory signals controlled by receptor
binding is involved (Parent et al., 1999). When the receptor binds to the
chemoattractant, the excitation signal increases greatly and a response is generated until
the inhibition signals reach the same level. If the excitation signal at the front of the cell
exceeds the inhibitory signal at the back this generates a persistent excitation signal with
the back of the cell the inhibition signal predominates and there is no response. Within
this model, the duration of the response is related to the cells position within the
gradient. The signal results in polymerisation of the cells F-actin at the site closest to
the chemoattractant, leading to the formation of a new pseudopod, cell polarisation and
a protrusion at the leading edge. This is followed by the assembly of conventional
nonmuscle myosin and retraction of the posterior of the cell (Parent et al., 1999).
The /3-defensins have displayed chemoattractant properties with a variety of cell
types. In order to elicit a coordinated response against invading pathogens specific cell
types have to be recruited to sights of bacterial entry. Leukocyte recruitment occurs
along gradients of chemotactic factors and is evident at nanomolar concentrations
(Baggiolini et al., 1998). Initially FIBD1 and HBD2 were observed to recruit both
human immature dendritic cells and memory peripheral blood memory T cells (Yang et
al., 1999). Additional studies involving the /3-defensins showed that chemotaxis was
evident with various defensins. FIBD3 and HBD4 are shown to be chemoattractant for
monocytes/macrophages (Garcia et al., 2001a, Garcia et al., 2001b). Activity with mast
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cells has also been observed. HBD-2 has been shown to activate rat mast cells and in
addition promotes the release of histamine and prostaglansin D2 (Niyonsaba et al.,
2001).
The /3-defensins have been shown to use chemokine receptor 6 (CCR6) (Yang et
al., 1999) which is also the receptor for Macrophage Inflammatory Protein 3 alpha
(MIP-3q;)/CCL20. The /3-defensins have also been shown to be displaced from the
CCR6 transfected cells by the chemokine MIP-3a suggesting that both have similar
motifs.
The molecular details behind the receptor mediated chemotaxis of the /3-
defensins are unknown. The inclusion of the cysteine residues is thought to be
important for chemoattractant properties. Using HEK293 cells expressing the human
CCR6 cells Wu et al., 2003 demonstrate that disulfide deficient HBD-3 displays no
chemoattractant properties although peptides with different disulfide connectivities
show a variation of activity. Some of these isoforms display enhanced chemoattractant
properties suggesting a role of the topological motifs surrounding the disulfide sites in
the receptor binding and activation ofHBD-3 (Wu et al., 2003).
The primary structures of HBD1, HBD2 and MIP-3o; display very weak
homology but a few similarities were identified at the tertiary structural level (Hoover et
al., 2002; Perez-Canadillas et al., 2001). The shallow grove between the N-loop and the
/32- /33 hairpin potentially create the region and specificity required for binding (Figure
1.7) The N-terminal DCCL motif in MIP-3o: plays a role in receptor interactions and it
has been postulated that HBD1 and HBD2 carry similar motifs (DHY in HBD-1 and
DPV in HBD-2) (Pazgier et al., 2006). Both MIP-3ci! and the /3-defensins share some
similarity in the distribution of their positively charged residues on the molecular
surface and surprisingly MIP-3a displays antimicrobial properties (Yang et al., 2003).
1.8.3 Additional activities of the defensins
In addition to their direct antimicrobial activity and chemoattractant properties a
number of other activities have been observed with the defensins (Figure 1.8). Human,
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rabbit and guinea pig odefensins are able to induce mast cell degranulation resulting in
the release ofmast cell granule products including histamine (Befus et al., 1999).
HNP1-HNP3 can augment IL-8 gene transcription and IL-8 production by
bronchial epithelial cells (Van Wetering et al., 1997). As mast cell degranulation brings
an influx of neutrophils (Malaviya et al., 1996) and IL-8 works as a potent
chemoattractant (Baggiolini et al., 1998), antimicrobial peptides may indirectly promote
the recruitment and accumulation of neutrophils at inflammatory sites.
Human odefensins have been shown to display activity with complement.
Human odefensins can bind to complement Clq to either enhance or suppress the
activation of the classical pathway in vitro (Prohaszka et al., 1997; van den Berg et al.,
1998). Presumable odefensins exhibit similar activity in vivo in regulating the function
of the complement system (Yang et al., 2004).
The odefensins have also been reported to inhibit the production of
immunosuppressive adrenal steroid hormones (Tominaga et al., 1990). odefensins
levels within the plasma can increase during systemic infection and have shown to
interfere with the production of adrenal glucocorticoids. As the glucocorticoids are
potent immunosuppressive mediators, the odefensins may also enhance systemic
antimicrobial immunity in vivo by inhibiting the production of glucocorticoids (Yang et
al., 2004).
The defensins also play an important role within the adaptive imuune system
regarding dendritic cells. Immature dendritic cells (iDCs) take up antigens at the site of
microbial entry. While processing the antigens the iDCs mature in response to
microbial products and mediators to mature dendritic cells (mDCs). The recruitment
and maturation of dendritic cells is essential for the induction of the adaptive immune
response. Defensins have been found to be direct chemoattractants for iDCs interacting
with CCR6 a G-protein coupled chemokine receptor. HBD1 and HBD2 are selectively
chemotactic for human iDCs but not mDCs (Yang et al., 1999).
A fusion peptide including mBD2 has been shown to induce the maturation of
iDCs into mDCs characterised by the upregulation of CD86, MHC II and CCR7
(Biragyn et al., 2002).
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The effect of defensins on DCs and T lymphocytes predicts that they may
contribute to the induction of adaptive antimicrobial immunity. The odefensins have
shown in vivo immunoenhancing activity. HNP1-HNP3 can enhance antigen specific
immune responses when coadministered with ovalbumin. The production of ovalbumin
specific serum IgG antibody and the generation of IFNy, IL-5, IL-6 and IL-10
providing evidence that the a-defensins can promote humoral and cellular adaptive
immune responses (Lillard et al., 1999).
The /3-defensins have been shown to enhance antigen specific immune responses
by the use of a DNA vaccine (Biragyn et al., 2002; Biragyn et al., 2001). mBD2 and 3
were fused with sFv38 a B-cell epitope and used to immunise mice. Potent humoral
immune responses against the non immunogenic sFv38 were displayed in addition to
antitumor protection.
While advances have been made in the development of defensins as
therapeutics, there are still no peptides clinically available. The problems associated
with these peptides hinders their current use as potential agents but further investigation
will provide knowledge required to develop these agents.
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1.9 AIMS OF THESIS
The work in this thesis aimed to analyse the activities of various murine /3-
defensins in an attempt to relate structure to function.
1. To evaluate the antimicrobial and chemoattractant properties of a novel five
cysteine defensin related peptide (Defrl)
2. To analyse Defbl4, the murine orthologue of human (3 -defensin 3 (HBD3)





2.1 Chemicals and oligonucleotides
All chemicals unless otherwise stated were obtained from Sigma Chemical
Company (Poole, UK) and were of the highest grade possible.
2.2 Cell lines and handling
See Table 2.1 for list of cell types used. All tissue culture work involving the
use of human, animal primary or transformed cells was performed using a vertical
laminar flow hood (BionMat2, Manchester UK). Cells were grown in incubators
maintained at 37°C with a 5% CO2 atmosphere. Confluent cultures of all adherent
cells were passaged by trypsin ethylenediamine tetra-acetic acid (trypsin-EDTA).
Briefly, cells were washed twice with sterile phosphate buffered saline (PBS) and
incubated at 37°C in 2 mL trypsin-EDTA (0.05% trypsin, 0.02% EDTA) for
approximately 5 minutes, or until the majority of cells had rounded and detached
from the flask. The action of trypsin-EDTA was then blocked with the addition of an
equal volume of complete media. Cells were harvested by centrifugation and then
resuspended in 10 mL of fresh media before plating.
2.3 Cell Isolation
2.3.1 Neutrophil isolation
The isolation of neutrophils was based on a method from Rot (1991). Adult
mice were injected peritoneally with 0.5 mL 9% (w/v) casein solution. A second
dose of casein was administered 24 hr later and after a further 3 hours the mice were
killed by cervical dislocation. The peritoneal cavity was lavaged using 5mL
Dulbeccos modified eagles medium (Invirogen, Paisley UK) DMEM /0.5mM EDTA
and the collected fluid placed on ice (Casein injections, cervical dislocation and
lavage performed by Dr Sheila Webb MRC Human Genetic Unit). To this a further
16 mL of ice cold 0.83% (w/v) ammonium chloride (pH 7.4) were added to the
lavage and incubated for 15 min at room temperature. 30 mL of Hanks Buffered Salt
Solution HBSS (Invitrogen) were added and the sample centrifuged for 10 min at
880 x g. The supernatant was removed and 10 mL HBSS was added, centrifuged for
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centrifuged at 496 x g for 10 min. The resulting pellet was resuspended in 500 pi of
PBS. A total cell count was performed using a Neubauer hemocytometer chamber
(VWR International Ltd, Poole UK) and the percentage of neutrophils estimated
from a DiffQuick (Raymond A Lamb Ltd, Eastbourne UK) differentially stained
cytospin (Shandon Scientific Ltd, Runcorn UK). Samples with over 90% neutrophils
were resuspended in DMEM/0.5mM EDTA for further experiments.
2.3.2 CD4+T-lymphocyte isolation
CD4+ T cells were isolated by a mini MACS magnetic cell sorter (Miltenyi
Biotech, UK) using a positive selection protocol. The mice were killed by cervical
dislocation and the spleen removed and placed in PBS. The spleen was homogenised
and centrifuged at 496 x g for 5 mins. The pellet was resuspended in 1 ml ofMACS
buffer (PBS, 2mM EDTA, 0.5% BSA & 0.1% sodium azide) and viable cells counts
were determined using a haemocytometer and 10% trypan blue solution. To
the remaining cells, CD4 (L3T4) magnetic microbeads (Miltenyi Biotec, UK) were
added and the cells incubated at 4°C for 15 min. While incubating 500 pi ofMACS
buffer was added to the LD MACS separation column (Milteny Biotec, UK) on three
occasions. After incubation of the cells with the magnetic beads, the suspension was
made up to 5 mL using MACS buffer and centrifuged at 496 x g for 5 min. After
centrifugation, the pellet was resuspended in 250 pi of MACS buffer and added to
the magnetic separation column. 2 x 500 pi of MACS buffer were added to the
column following the sample to wash through any negative isolation. The column
was removed from the magnet and placed over a universal to collect the positive
isolation. 2mL of MACS buffer was added to the column and pushed through using
the column plunger to collect the sample. The samples were centrifuged and
resuspended.
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2.3.3 Human monocyte and T cell isolation
Mononuclear cells were isolated from human peripheral blood or bone
marrow of normal donors by routine Ficoll-Paque density gradient centrifugation.
CD34+ cells were then purified from the resulting mononuclear cells with a magnetic
cell sorter CD34 progenitor isolation kit (Miltenyi Biotech) and peripheral blood T
cell subsets were purified with human T cell subset enrichment columns (R&D
systems). Protocolperformed and optimised by De Yang (Frederick, USA).
2.4 Chemotaxis Assay
Chemotaxis was perfomed using a 96 well chemotaxis chamber (Neuro Probe
Inc, Gaithersburg USA). 30 pi of sample was loaded into the bottom chamber
including the positive and negative controls, which were all assayed in triplicate. All
murine chemokines (SDFla, fMLP & CCL20) were purchased from PeproTech EC
(London, UK) and dissolved in RPMI / 1% BSA. Negative control for this assay
consisted of RPMI / 1% BSA (chemotactic media alone). Stock solutions were
prepared at 5 pg/ml. A polycarbonate filter (Neuro Probe Inc, Gaithersburg USA)
was added to the top chamber against the silicon gasket and carefully placed on top
of the bottom chamber to eliminate air bubbles. The chamber was carefully
assembled and incubated at 37 °C while preparation of the cells occurred. Cells were
prepared in RPMI / 1% BSA and 225 pi added to the wells in the top chamber at 1-5
x 105 cells/mL. The chamber was incubated in a humid 5% CO2 incubator for a
period of time specific to the cell type being studied (Table 2.2). Once incubation
was complete the top chamber was removed and inverted. The filter was removed
and the side with the non-migrating cells was washed in PBS to remove any cells that
may interfere with staining. Wells within the lower chamber were counted to detect
any cells that had passed through the filter and failed to adhere to the underside. No
cells were detected in the lower wells.
Chemotaxis assays involving human cells were performed by De Yang
(Frederick, USA). In addition checkerboard assays, whereby the same concentration
of peptide is present in the upper wells in addition to that in the lower wells were
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determine if the migration observed was directed (chemotaxis) or random
(chemokinesis). Chemokinesis was not observed only chemotaxis (Personal
communication De Yang Frederick, USA).
2.4.1 Staining of filters
For all cell types used the filter was allowed to air dry and subsequently
immersed in solution A (methanol fixative) of DiffQuick for 2 min. The filter was
removed and stained with solution B (Azure B) for 2 min and solution C (Eosin) for
2 min. Once the staining protocol was complete the filter was gently rinsed in sterile
water and allowed to dry.
2.4.2 Filter Counts
Three random fields of view were counted for every well. The mean number
of cells migrated and the standard error of the means (SEM) were calculated. In
addition counts were performed on the lower wells to assess for cells that passed
through the filter and failed to adhere to the underside. No cells were present in the
lower wells.
2.5 Haemolysis assays
Erythrocytes were collected in vacuum tubes containing heparin as an
anticoagulant. The erythrocytes were harvested by centrifugation for 7 min at
4000rpm and washed three times in Tryptone soya broth (TSB) (Oxoid,Basingstoke
UK) supplemented with 287 mM glucose. The pellet was resuspended in TSB + 287
mM glucose and diluted 1:50. 100 pi of the suspension was added to different
amounts of the peptide in V-bottomed 96 well plates (Greiner Bio-One Ltd,
Stonehouse UK), resulting in peptide concentrations in a range of 3.8 to 500 pg/ml.
The plates were incubated for 60 min at 37 °C and centrifuged at 1488 x g for 5 min.
The supernatants from each well were transferred to a flat bottom 96-well plate
(Greiner Bio-One Ltd). The release of haemoglobin from the lysed erythrocytes was
measured at 550nm.
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The percentage haemolysis was calculated by:
(A550 peptide treated sample - A55o media treated sample)
xl00%
(A550 of Tween-20 treated sample - A55o media treated sample)
All experiments were performed in triplicate on three independent occasions.
2.6 Tricine gel electrophoresis
2.5 pg of peptide was dissolved in 2.5 pi of 0.01 % acetic acid and 5 pi of 2x
sample buffer (Novex Tricine/SDS sample buffer LCI676). Reduction of samples
was performed by adding 10 mM of NuPage sample reducing agent (Invitrogen
NP0004) and incubated at 80 °C for 5 min. The entire sample was loaded on a 16%
tricine gel and run in Novex tricine running buffer (lOx) (Invitrogen). The gel was
fixed and stained with coomassie blue stain.
2.7 Preparation of RNA
2.7.1 RNA from tissues
All RNA preparations were performed in a double HEPA filter hood
(Medical Air Technology, Manchester UK) using RNase and Dnase free filtered tips.
Tissue samples were homogenised using an Omni portable homogeniser (Camlab
Ltd, Cambridge UK) in 1 mL of RNAzol B (Biogenesis Ltd, Poole UK) until
completely lysed. Samples were transferred to a fresh screw top eppendorf to which
100 pi of chloroform was added and vortexed for 15 seconds. The samples were
incubated on ice for 5 min and centrifuged at 20380 x g for 15 min at 4 °C and the
top layer carefully transferred to a fresh tube on ice without disturbing the lower
layer. To this an equal volume of ice cold isopropanol was added and incubated on
ice for 15 min. The samples were centrifuged at 20380 x g for 15 min and the RNA
pellet was washed with 75 % (v/v) ice-cold ethanol and allowed to dry. The RNA
was resuspended in 50pl DEPC treated water and assessed by spectrophotometry.
The ratio between the absorbance values A260/A280 gives an estimate of the RNA
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purity. A ratio of 2.0 is observed for pure RNA. Samples with lower ratios were
discarded. Ratios, concentrations and absorbance were all calculated automatically
by the spectrophotometer.
2.7.2 DNase treatment of RNA
To remove any DNA present in the RNA samples, Dnase 1 RNase-free
(Roche) was used. The samples were treated using 10 x Dnase 1 buffer, 10 units
Dnase 1 and 40 units of RNA inhibitor. The samples were incubated at 37 °C for 60
min and then extracted using an equal volume of phenol:chloroform, vortexed and
centrifuged at 20380 x g. The top layer was carefully transferred to an equal volume
of chloroform, vortexed and centrifuged at 20380 x g for 15 min. The top layer was
transferred to a fresh tube on ice and 0.1 volumes of 3 M sodium acetate (pH 5.6)
and 2 volumes of ethanol were added. The samples were incubated at -70 °C for 30
min. The sample was centrifuged at 20380 x g for 15 min and the pellet washed in
70 % (v/v) ethanol. The pellet was dried and resuspended in DEPC H20.
2.8 Amplification ofRNA and DNA by Polymerase Chain Reaction
All PCR reactions were performed using filtered RNase and DNase free tips.
2.8.1 Amplification from RNA
Amplification ofRNA was carried out using a first strand cDNA synthesis kit
for RT-PCR (AMV) Roche UK. Duplicate samples of 2 pg ofRNA in a total volume
of 7.8 pi DEPC treated H2O were denatured for 15 min at 65 °C. To one set of
samples
2 pi of 10 x PCR buffer
4ul MgCl2
2 pi 10 mM dNTPs
0.4 pi gelatin
2 pi of random primer p(dN)6
40 units RNase inhibitor
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0.8 )_i 1 DEPC treated H2O or 0.8 jal AMV reverse transcriptase
RNA minus sample was included in the set as a control for contamination. The
samples were incubated at RT for 10 min to allow the primers to anneal then
incubated at 42 °C for 60 min followed by 5 min at 95 °C to inactivate the AMV.
Once cooled 5 pi was removed and used in the PCR reaction described next.
2.8.2 Amplification from DNA
1 pg cDNA
5 pi 25 mM MgCh
5 pi 10 x PCR buffer
5 pi DMSO
1 pi of 50 x dNTP mix (10 mM of each nucleotide)
1 pi of 100 mM forward and reverse primers
0.5 pi of thermostable DNA Taq polymerase
(All PCR reagents were purchased from Invitrogen)
The above were added to a thin wall eppendorf. A programmable heating block
(OmniGene, Hybaid) controlled thermal cycling. The following PCR reaction was
utilised for all the defensins genes with the exception of varying annealing
temperatures that differed depending on the melting point of the primers (Table 2.3).
PCR cycle conditions
Step 1: 94 °C for 3 min
35 cycles of:
Step 2: 94 °C for 1 min
Step 3: (annealing temperature) for 30 seconds
Step 4: 72 °C for 1 min
Final Step 5: 72 °C for 10 min
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2.83 Agarose gel electrophoresis
Agarose gel electrophoresis was performed using gel apparatus (Bioscience
Services). Gels were prepared at 1 - 1.5 % agarose depending on the resolution
required. The agarose was dissolved in TBE buffer (0.09 M Tris-borate, 0.002 M
EDTA (pH 8.0) and ethidium bromide (5 pg/100 ml)(BioRad). Gels requiring
resolution of DNA fragments below 200bp used Nu-SIEVE agarose gel (FMC Bio
Products). Gels were run in TBE buffer at 100 V for 90 min and bands detected
using a UV illuminator.
2.84 Southern blot transfer of DNA
Once the DNA fragments were separated by gel electrophoresis the gel was
soaked in denaturing buffer (0.5 M sodium hydroxide and 1.5 M sodium chloride)
for 20 min. The gel was transferred and soaked in neutralising buffer (0.5 M Tris,
1.5M sodium chloride) for 10 min. The gel was then transferred onto Hybond-N
(Amersham Biosciences) by capillary transfer overnight in 20 x SSC (3M sodium
chloride, 0.3M sodium citrate). The membrane was removed and blotted dry before
being UV stratalinked (Stratalinker 1800, Stratagene).
2.9 Radioactive Hybridisation
2.9.1 Preparation of radioactively labelled oligonucleotide probes
50 ng of oligonucleotide probes (15-25bp in length) were labelled in a total
volume of 20 pi. 2 pi of 10 x polynucleotide kinase (PNK) buffer, 10 units of PNK
and 30 pCi [y-32P] dATP. The reaction was incubated for 1 hour at 37 °C and then
added to the prehybridised filter.
2.9.2 Hybridisation of radioactive oligonucleotide probes
Filters were pre-hybridised at 48 °C for 4 hours in a rotating hybridisation
bottle. This contained 20-30 mL oligonucleotide hybridisation buffer (3 M sodium
chloride, 0.3 M trisodium citrate, 0.4 % SDS and 0.2 % sodium pyrophosphate) and
1 mg of sonicated salmon sperm. After pre hybridisation, radiolabelled
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oligonucleotides were added directly to the bottle and the solution and blots
hybridised for 4 hour at a temperature 4-6 °C lower than the melting temperature of
the oligonucleotide. Filters were then washed with 6 M sodium chloride, 0.6 M
trisodium citrate and 0.1 % SDS. The filters were placed in a cassette and exposed to
Kodak X-Omat AR film at -70 °C.
2.10 Bacterial killing assays
Test organisms (Table 2.4) were grown to mid-logarithmic phase in Iso-
Sensitest broth (ISB) (Oxoid) growth media and then diluted to 1-5 x 106 colony-
forming units (CFU)/ml in 10 mM potassium phosphate containing 1% (v/v) Iso-
Sensitest broth, pH 7.4. Different concentrations of test peptide were incubated in
100 pi of cells (1-5 x 105 CFU) at 37 °C for 3 h. 10-Fold serial dilutions of the
incubation mixture were plated on Iso-Sensitest agar (ISA) plates, incubated at
37 °C, and the CFU determined the following day. The minimum bactericidal
concentration (MBC) is the concentration of peptide where we observed >99.99%
killing of the initial inoculum. All assays were performed in triplicate on three
independent occasions. The MBC was obtained by taking the mean of all the results,
and experimental errors were within one doubling dilution. Assays involving DTT
require 10 mM of Nupage sample reducing buffer (Invitrogen) to be added to the
peptide stocks before commencing the bacterial killing assays.
2.10.1 Salt sensitivity killing assays
To the 10 mM potassium phosphate buffer + 1 % ISB, sodium chloride was
added between 0 mM - 250 mM and applied to each individual peptide
concentration. The assay was performed as described above.
2.10.2 Serum killing assays
To the 10 mM potassium phosphate buffer + 1 % ISB, human serum (pooled,
heat inactivated) was added (ICN Biomedicals, USA). Various percentages 0.1, 1 &
10 % were evaluated at each individual peptide concentration. The assay was
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2.11 Peptide Synthesis
All peptides were chemically synthesised by standard solid phase
methodology. Defbl4, Defbl4 1 cys, hBD3, Defrl, Defrl 1 cys & 5YC were
obtained from Chemical Synthesis Services-Albachem Ltd (Gladsmuir, UK). The
Defbl4 inspired peptides were made in-house using automated peptide synthesis
(Applied Biosystems 433A peptide synthesizer) using Rink amide AM resin for
peptide amides, pre-loaded NovaSyn TGT resin for peptide acids and Fmoc amino
acids (Novabiochem). The identity and purity of all peptides was confirmed by LC-
mass spectra (Micromass Quattro LC mass spectrometer). Semi-preparative HPLC
was performed using a Phenomenex Luna CI8 column and a gradient of 5-95%
acetonitrile (containing 0.1% TFA) over 45 min (flow rate of 3.0 mL/min).
Automated solid phase synthesis was carried out on a 0.05 mmol scale using 0.5
mmol of each Fmoc amino acid per coupling reaction and HBTU/FIOBt as coupling
reagents. The coupling time was 0.5 h. Peptide products were cleaved from the
resin with 95 % TFA, 2.5 % ethanedithiol, 2.5 % water for 3 hours. The resin was
filtered-off, washed with TFA, and filtrate poured into diethylether (10 volumes),
centrifuged for 3000 rpm for 15 min, resuspended in ether and re-centrifuge for 3000
rpm for 15 min. The crude peptides were dissolved in water and loaded directly onto
a semi-preparative FIPLC column. Peptide fractions were identified by mass
spectrometry and lyophilised. Protocol optimised and performed by Derek
MacMillian, Department ofChemistry, University College London, London.
2.12 Mass spectrometry measurements
Accurate mass measurements were performed using a 9.4 T FT-ICR mass
spectrometer (Bruker Daltronics). The peptides were electrosprayed at a
concentration of 20 pM from a solution of 50:49:1 water/methanol/acetic acid (v/v).
The resulting spectra were calibrated externally using 20 pM ubiquitin. A Q-TOF
mass spectrometer (Micromass) was employed to obtain masses of all peptides. All
peptides were first prepared in 10 mM ammonium acetate, pFI 6.4 and analysed by
nano-electrospray MS. Protocol optimised and performed by Bryan McCullough,
School ofChemistry, University ofEdinburgh, Edinburgh.
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2.13 Disulfide connectivities
The disulfide connectivities were determined by proteolysis and peptide mass
mapping. A 50 pM solution of the peptide was subjected to proteolytic cleavage
with trypsin (for Defbl4) and a combination of trypsin and chymotrypsin for HBD3.
The digested peptides were analysed using LC-MS (Micromass Platform I) and by
nano electrospray using a Q-ToF (Micromass). For analysing HBD3, a MALDI-
TOF mass spectrometer (Voyager Discovery (Applied Biosystems)), and a FT-ICR
MS were used. Protocol optimised and performed by Dave Clarke, School of
Chemistry, University ofEdinburgh, Edinburgh.
2.14 Nuclear Magnetic Resonance
The ID 1H NMR spectra of the peptides were measured using a Bruker 600
MHZ Avance NMR spectrometer equipped with a 5mm triple resonance cryoprobe
with z-gradients. Samples (250 pg) were dissolved in 550 pi of a 9:1 mixture of
H20:D20. The pH was adjusted to 3.5 and 512 and 1024 scans were accumulated at
298 °C in each spectrum. A double pulse field gradient spin-echo was used to
suppress the water. Protocol optimised and performed by Dusan Uhrin, School of
Chemistry, University ofEdinburgh, Edinburgh.
2.15 Defrl HPLC fractions
The peptide was fractioned on a gradient of 20-30%B in 60mins on a Jupiter C5 250
x 10mm semi prep column at a flow rate of 51/min. 5ml fractions were collected
throughout the region of interest and lyophilised and redissolved in 1 ml of water.
Protocol optimised and performed by Albachem Ltd, Elvingston Science Centre,
Gladmuir, East Lothian.
2.16 Statistical analysis
Regarding chemotactic analysis the counts from each well in the chamber
were classified by agent, experiment and concentration. The data were transformed
to log (x) and ((x+3/8)). Means were taken from both the transformed and
untransformed data classified by experiment, agent and concentration to which were
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tested for homogeneity of variance between each of the treatment groups. A
preliminary analysis of variance was done including all main effects and two-factor
interactions of the factors experiment, agent and concentration. When either of the
two-factor interactions with experiment were not significant (p>0.2) they were
removed from the model to help to increase the degrees of freedom available for
estimating error. Analysis of variance was then repeated for each case and produced
a table classified by the factors agent x concentration, which displayed means,
standard errors of means and Minimum Significant (at 5%) Difference (MSD) all
shown graphically.
Regarding antimicrobial analysis the data were classified by factors of serum
concentration both treated and untreated with the peptide and the number of replicate
experiments. Between group variances were stabilised with loge(l+x)
transformation). The data were transformed and averaged over the replicate
experiments. A three-factor balanced analysis of variance was done using the three-
factor interaction as the error term. When other two-factor terms were found to be
non significant they were removed from the model and fitted valued recalculated
increasing the number of degrees of freedom for error and reducing the confidence
range. Tables of the transformed data displaying standard errors were produced and
represented graphically. All statistical analyses were performed using either Minitab
for Windows (Minitab Inc, Philadelphia, USA) or Microsoft Excel (Microsoft
Corporation, USA). Data was considered significant in all cases at p<0.05.




ANALYSES OF A NOVEL FIVE CYSTEINE
DEFENSIN RELATED PEPTIDE (Defrl)
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3.1 INTRODUCTION
Mammalian host defence peptides are diverse in size, structure and function.
Over a thousand peptides have been identified from various sources and this continues to
expand. Differences in net charge, hydrophobicity and sequence of the peptides allow
efficient characterisation and subgrouping of families.
Various peptides have been shown to contain cysteine residues which in turn are
responsible for numerous disulfide bonds. With the /3-defensins the cysteine residues are
reported to be essential for chemoattractant properties but not necessarily for the
antimicrobial components (Wu et al., 2003). Multiple families display disulfide bonds
within their peptides varying in the number and the position. The mammalian
antimicrobial peptide lactoferricin is a 25 residue antimicrobial peptide derived from the
N-terminus of lactoferrin (Bellamy et al., 1992) by gastric proteolytic cleavage. This
peptide contains one disulfide bond and displays potent antimicrobial activity through its
homologues with bovine lactoferricin being the most potent (Vorland et al., 1998).
Protegrin derived from porcine leukocytes contain two disulfide bonds reported to
stabilize the /3-sheet structure. This peptide is an 18 residue broad spectrum
antimicrobial agent with activity against the highly resistant Neisseria gonorrhoeae (Qu
et al., 1997). Hepcidin, a urine antimicrobial peptide predominantly expressed in the
liver (Park, et al 2001) contains four disulfide bonds. Hepcidin has been shown to
display both antifungal and antibacterial properties.
The /3-defensins exhibit three disulfide bonds within their peptide structure. The
majority of /3-defensins display these properties although exceptions can be found. An
intragenic polymorphism of the DEFB1 gene changes a highly conserved cysteine
residue to a serine residue (Circo et al., 2002) As a result of this coding one cysteine
remains unpaired and HBD1 is unable to form three disulfide bonds. A synthetic HBD-
1 with the variant serine in place of the cysteine residue has been synthesised and tested
for antimicrobial properties. The variant HBD-1 still retains antimicrobial properties
against P.aeruginosa and C.neoformans comparable with that of the parent HBD-1.
A murine /3-defensin gene present in C57B16 mice has been discovered to encode
a peptide with only five cysteine residues (Morrison et al., 2002). This peptide Defrl
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displays a tyrosine in place of the first cysteine and yet retains potent antimicrobial
activity against gram positive and negative organisms. This gene is a variant allele of
Defb8 which encodes six cysteines and is present in all the other inbred murine strains
tested. Defb8 has very high levels of identity (98%) with Defrl differing only in three
amino acids residues (Bauer et al., 2001).
The expression of Defrl was analysed extensively in various murine tissues and
detected prominently in the heart, testis and to a lesser extent the uterus. Previously
Defrl was synthesised and tested for activity. Morrison et al., 2002 reported that a
synthetic Defrl peptide displayed antimicrobial activity with S.aureus, E.coli and
B.cenocepacia and this was subsequently diminished in the presence of various salt
concentrations with the exception of P.aeruginosa to which Defrl retained its
antimicrobial properties. Recently the relationship between the structure and activity of
Defrl and its six cysteine analogue has been studied (Campopiano et al., 2004). The
peptide 5YC involves reinstating the cysteine residue at the proposed site which is
currently occupied with a tyrosine residue. By using electrophoresis and mass
spectrometry Defrl and 5YC were shown to be defensin dimers, Defrl mediated by an
intermolecular bond and 5YC three intramolecular bonds (Campopiano et al., 2004).
Connectivities of both were conducted using mass mapping and concluded that 5YC
showed the /3-defensin disulfide bond connectivity whereas the oxidised Defrl is a
mixture of different dimeric isoforms with unknown inter- and intramolecular
connectivities. The differences in antimicrobial properties were studied against
P.aeruginosa. Oxidised Defrl displayed significantly more activity than its reduced
form and that of both the oxidised and reduced 5YC. Further analysis involved varying
salt concentrations in the antimicrobial assays. Defrl displayed antimicrobial activity at
150 mM NaCl whereas 5YC was inactive at that concentration.
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AIMS
The aims of this chapter were to:
1 Evaluate the antimicrobial properties of Defrl and 5YC against a panel of
microorganisms, including multi resistant isolates
2 To analyse Defrl fractions collected by HPLC for antimicrobial
properties
3 To examine the chemoattractant properties ofDefrl and 5YC




A synthetic preparation of Defrl was examined in order to characterise the
antimicrobial (Table 3.1) and chemoattractant properties (Table 3.6). Defrl HPLC
fractions were collected to examine for antimicrobial activity. A six cysteine analogue
5YC which involved reinstating the cysteine residue at the proposed site which is
currently occupied by a tyrosine residue was studied for antimicrobial and
chemoattractant properties. In addition a one cysteine variant Defrl leys was created to
validate the essentiality of a covalent dimer structure in functionality.
3.3.1 Antimicrobial activity of Defrl and 5YC against a panel of multi-resistant
strains
Antimicrobial analysis was performed on both Defrl and 5YC (Table 3.1)
against a panel of micro-organisms, Gram positive, negative bacteria and fungi (Figure
3.1-3.5). Defrl displayed potent antimicrobial activity against a spectrum of organisms
(Table 3.2). The majority of organisms gave MBC values with Defrl, 3-10 gg/ml with
the exception of >100 pg/ml for B.cenocepacia. Defrl gave notable activity against the
multi resistant pathogens, A.baumannii 3 ug/ml (p<0.01), S.maltophilia 12.5 ug/ml and
P.aeruginosa PAOl 6 jig/ml (p<0.01). 5YC displayed poorer activity against the
different isolates {A.baumannii 12.5 pg/ml (p<0.01), P.aeruginosa 50 pg/ml (p<0.01)
and C.albicans 25 pg/ml (p<0.01)) requiring higher concentrations of the peptide to give
complete killing.
3.3.2 Gel electrophoresis of Defrl fractions
In order to characterise Defrl HPLC fractions were collected (Procedure
performed and optimised by Albachem Ltd, (Appendix 1)). As Defrl is a complex mix
the aim of the fractions was to isolate specific isoforms from the mix in hope of
displaying various activity profiles. Fractions were analysed by gel electrophoresis on a
16% tricine gel alongside a sample of Defrl from the previous preparation (Figure 3.6).
Defrl revealed a prominent upper band at around 7kDa and a faint lower band migrating
around 4kDa. The fractions run gave clear differences throughout the two gels. The
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Figure 3.1 Antimicrobial activity of Defrl and 5YC against A.baumannii U45
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 3.2 Antimicrobial activity of Defrl and 5YC against C.albicans J2922
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 3.3 Antimicrobial activity of Defrl and 5YC against E.faecalis ATCC 29212
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 3.4 Antimicrobial activity ofDefrl and 5YC against P.aeruginosa PAOl
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =




























Figure 3.5 Antimicrobial activity of Defrl and 5YC against S.aureus MRSA J2918
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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7kDa upper band change in intensity throughout the samples and towards the end,
fractions 10-14, the band diminished in thickness.
3.3.3 Antimicrobial activity of Defrl fractions
Due to the clear differences observed in the above gels, the antimicrobial activity
was analysed to ascertain any differences between the fractions. All fractions were
tested against P.aeruginosa (Table 3.3) giving MBC values of 6 ug/ml. No differences
were detected between the fractions.
3.3.4 Mass spectrometry ofDefrl fractions 2, 9 and 13
Due to the differences visable by gel electrophoresis, 3 fractions were chosen for
mass spectrometry. Fractions 2, 9 and 13 were analysed by Q-ToF and performed by
Bryan McCullough (Figure 3.7). All three fractions revealed similarities, all showing
dimeric properties similar to the original Defrl preparation (personal communication
Perdita Barran).
3.3.5 Antimicrobial activity ofDefrl fractions 2, 9 and 13
Fractions 2, 9 and 13 were reduced with DTT to determine if a change from
oxidised to reduced form would alter the antimicrobial properties against P.aeruginosa
PAOl (Table 3.4). Antimicrobial activity was abolished with the presence of DTT
(Figure 3.8). Fractions 2, 9 and 13 previously giving MBC values of 6 pg/ml (p<0.01)
were increased to values >50 pg/ml in the presence ofDTT.
3.3.6 Antimicrobial activity of Defrl leys
A synthetic one cysteine dimeric analogue of Defrl (Table 3.1) was created and
analysed for antimicrobial function. Defrl leys was synthesised in an attempt to create
a single defined species as Defrl is a mixture. Defrl 1 cys was synthesised, folded and
was shown to be a homodimer by Albachem Ltd (personal communication Albachem
Ltd). Defrl leys displayed potent antimicrobial activity against the panel of
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Figure3.7MassspectrometryofDefrlfractions2,9nd13 Theabovefigurdisplaystm sspectrometryofhreeDef l1fracti n(fracti2,9nd3-r rAp e dix).ll threesampl sdi p ayi ilarmasspectrometryraceresultinginof7566D ,7ndespectiv ly.T
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Figure 3.8 Antimicrobial activity ofDTT treated Defrl fractions
Graph A, B and C show the mean number of colony forming units (CFU) ± standard
error from the blank control and the peptide treated samples (+/- lOmM DTT) against
P.aeruginosa PAOl. ** = p<0.01, * = p<0.05. Experiments were repeated three times
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Figure 3.9 Antimicrobial activity ofDefrl leys and Defrl leys DTT against
A.baumannii ATCC 19606
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 3.10 Antimicrobial activity of Defrl leys and Defrl leys DTT against
B.cenocepacia J2315
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 3.11 Antimicrobial activity of Defrl leys and Defrl leys DTT against E.coli
ATCC 25922
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 3.12 Antimicrobial activity of Defrl leys and Defrl leys DTT against E.faecalis
ATCC 700802
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * -
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Figure 3.13 Antimicrobial activity of Defrl leys and Defrl leys DTT against
P.aeruginosa PAOl
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 3.14 Antimicrobial activity of Defrl leys and Defrl leys DTT against S.aureus
ATCC 25923
Graph A shows the mean number of colony forming units (CFU) ± standard error from
the blank control and the peptide treated samples. Graph B shows the mean percentage
kill; this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Defrl leys gave MBC values of 6 pg/ml and 12 pg/ml (Table 3.4). Further upon
treatment with DTT the antimicrobial activity of Defrl leys is diminished from 6-12
pg/ml to >50 pg/ml.
3.3.7 Mass spectrometry of Defrl leys
Defrl leys was analysed by Q-ToF MS by Bryan McCullough (Figure 3.15).
Defrl 1 was analysed at 10 gM 1:1 MeOFl/DfTO and displayed dimeric properties.
3.3.8 Gel electrophoresis of Defrland Defrl leys
Characterisation of the Defrl peptide on a 16% tricine gel revealed that the
preparation consists of a dominant upper band at 7kDa and a faint lower band at 4kDa
(Figure 3.6). However mass spectrometry showed it exists as a covalent dimer
(Campopiano et al., 2004). Reduction of Defrl with 10 mM DTT results in a shift of the
migration of the peptide to a stronger band at around 4kDa. Defrl leys displayed
similar mobility on the gel with a band around 7kDa for the oxidised Defrl leys and
upon reduction with DTT a shift is observed to around 4kDa (Figure 3.16)
3.3.9 Chemoattractant analysis of Defrl, 5YC and Defrl leys
Defrl, Defrl leys and 5YC were evaluated for chemotactic activity against
neutrophils, CD4+ T cells (human & mouse) and CCR6 expressing HEK293 cells
(Figures 3.17-3.20). The Defrl parent molecule displays chemotactic activity for CD4+
T cells, human and mouse, with an optimum concentration of 10 ng/ml (Table 3.6).
Defrl leys and 5YC also induce migration with optimum concentrations at 100 ng/ml.
The single cysteine dimer analogue displays ten fold greater activity in comparison with
the parent Defrl. No migration was observed with any of the peptides against murine
neutrophils. In addition no migration was observed with CCR6 expressing HEK293
cells.
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Figure 3.17 Migration ofmouse CD4+ T cells in response to Defrl Defrl leys and 5YC
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts. Experiments were
repeated three times and the above is a representative experiment (n=3).
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Figure 3.18 Migration of human CD4+ T cells in response to Defrl Defrl leys and
5YC
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts. Experiments were
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Figure 3.19 Migration ofmouse neutrophils in response to Defrl Defrl leys and 5YC
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts. Experiments were
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Figure 3.20 Migration ofHEK 293 CCR6 cells in response to Defrl Defrl leys and
5YC
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts. Experiments were
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3.4 DISCUSSION
Through evaluation of Defrl, 5YC and Defrl leys this study has shown the
following:
• That Defrl displays antimicrobial activity against a panel of microorganisms,
including multi-resistant isolates.
• That Defrl HPLC fractions are a mixture similar to that of the original Defrl.
• That Deffl HPLC fractions are similar by mass spectrometry and display
identical antimicrobial values against P.aeruginosa.
• That the synthetic dimeric analogue Defrl leys dimer displays antimicrobial
properties comparable with that of Defrl and upon reduction with DTT the
activity diminishes.
• That Defrl, Defrl leys and 5YC display chemoattractant properties for CD4+ T
cells
• That Defrl, Defrl leys and 5YC do not chemoattract using CCR6 expressing
HEK293, the proposed receptor for /3-defensin chemotaxis.
3.4.1 Antimicrobial analysis of Defrl and 5YC against a panel of multiresistant
organisms
Defrl and 5YC were both evaluated for antimicrobial activity against a panel of
organisms, including some multi-resistant, problematic isolates. Organisms including
Acinetobacter, Burkholderia, Ralstonia and Stenotrophomonas specieswere tested. The
gram negative Acinetobacter baumannii is generally considered non pathogenic but is
frequently isolated in nosocomial infections. A. baumannii causes mild to sever illness
but can be fatal due to its frequent resistance to establish antimicrobials (Joly-Guillou, et
al., 2005). B. cenocepacia are important opportunistic pathogens regarding cystic
fibrosis (Mahenthiralingam et al., 2005). Displaying natural resistance to many
antimicrobials B. cenocepacia causes variable lung infections resulting in chronic
infections often requiring isolation. Ralstonia species are generally considered to be of
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little clinical significance although reports have highlighted their role in bacteraemia
(Ryan et al., 2006). Invasive and severe infections have been reported with this
persistent nosocomial organism. Although uncommon Stenotrophomonas maltophilia
is difficult to treat due to its resistance to broad spectrum antibiotics. S. maltophilia is
commonly associated with infections of the tracheal tubes (McGowan et al., 2006).
Both Defrl and 5YC contain 34 residues and display an overall net charge of +6
(Table 3.1). The only notable difference is the replacement of a tyrosine residue with a
cysteine residue reinstating the /3-defensins cysteine backbone. Both peptides form
dimers (Campopiano et al., 2004) yet give different antimicrobial profiles against the
organisms tested. Defrl displays potent antimicrobial activity against a broad spectrum
of pathogens. This is the first documented study involving an extensive panel ofmulti-
resistant nosocomial isolates tested against a /3-defensin. A previous study regarding
HBD3 (Maisetta et al., 2006) involved analysing the antimicrobial activity of six
different isolates from S.aureus, E.faecium, P.aeruginosa, S.maltophilia and
A.baumannii. The A.baumannii isolates included bacterial strains that were resistant to
one or two classes of antimicrobials yet still gave an MBC value of 4 pg/ml (Maisetta et
al., 2006). Only the B.cenocepcia strains (Table 3.2) showed high levels of resistance to
Defrl (MB0100 jig/ml), a result which is in agreement with the characteristic
resistance of these bacteria to conventional antibiotics and antimicrobial peptides (Sahly
et al., 2003). Previously (Morrison et al., 2002b) reported that the bactericidal activity
of Defrl against B.cenocepacia J2315 gave only 40% killing when tested at 50 gg/ml.
Regarding 5YC this peptide displayed antimicrobial activity against a few isolates but
this required a higher concentration to observe killing than that with Defrl. The
majority of values observed were greater than 100 ug/ml. Previously, the differences in
antimicrobial activity between Defrl and 5YC were attributed to their structure
(Campopiano et al., 2004). 5YC forms a noncovalently bound dimer in solution and
retains the disulfide connectivity typical of that within the /3-defensins. Defrl reveals a
covalent dimer containing an intermolecular disulfide bond and is a complex mixture of
dimer isoforms, varying in intra and inter-molecular disulfide connectivities. Upon
reduction and subsequently a loss of structure, the antimicrobial activity of Defrl
80
I .
diminishes. Interestingly NMR studies of Defb8 / mBD-8 (Bauer et al., 2001) revealed
that this was a monomer, unlike that of the dimer evident with Defrl. mBD- 8 has been
synthesised (Kluver et al., 2002) but no functional studies of the peptide have been
published.
3.4.2 Defrl HPLC Fractions
HPLC was performed by Albachem Ltd and fractions collected, lyophilised and
resuspended in 0.01 % acetic acid. Gel electrophoresis and antimicrobial assays of the
fractions were performed. Antimicrobial analysis revealed that all the fractions and the
parent Defrl displayed activity at 6 pg/ml (Table 3.3). Gel electrophoresis of the
fractions revealed different intensities on the 16% tricine gel implying different
structures. Fractions 2, 9 and 13 were selected due to their noticeable differences on the
gel and studied by mass spectrometry (Figure 3.6 & 3.7). Despite the apparent mobility
differences the structure of the three fragments was consistent. Upon reduction of the
fractions with DTT the antimicrobial activity was diminished (Table 3.4) and mass
spectrometry confirmed the loss of dimeric structure. The revelation that Defrl contains
a mixture of different isoforms is not an unusual discovery with the /3-defensins.
Previous work on synthetic HBD3 led to the discovery that it did not fold into a single
isoform with the typical /3-defensin disulfide connectivity in vitro (Wu et al., 2003).
Instead, at least seven topologically distinct isoforms were isolated with unusual
intramolecular connectivities, all of which displayed similar antimicrobial activity.
3.4.3 Antimicrobial analysis of Defrl leys
In an attempt to confirm the importance of a dimeric-activity relationship, a one
cysteine variant (Table 3.1) was synthesised. Defrl 1 cys was tested antimicrobially
against both Gram positive and Gram negative organisms (Figure 3.9-3.14) and
displayed results similar to that of the original Defrl peptide. Defrl 1 cys forms a
covalent dimer and again similar to that of the original Defrlthe antimicrobial activity is
diminished and the dimeric structure is lost upon reduction with DTT. The presence of
DTT does not alter bacterial viability (personal communication Ross Langley). These
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results strongly suggest that it is the covalent dimerisation of Defrl that makes it a
powerful antimicrobial and the synthesis of Defrl 1 cys confirms this. Synthetic
sequences based on the Defrl /3-defensin sequence are antimicrobially potent even in the
absence of the canonical cysteine motif. This has been confirmed with HBD3 and the
synthesis of the peptide with the cysteines replaces with a-aminobutyric acid (Hoover et
a\., 2003). The peptide still retains its antimicrobial activity.
3.4.4 Chemotactic analysis of Defrl, 5YC and Defrl leys
Many /3-defensins can act as chemoattractants for cells involved in host defense.
Defrl, 5YC and Defrl leys were evaluated against a panel of different cell types.
Chemotaxis was observed using CD4+ T cells. This is not an unusual observation as
various defensins have displayed the ability to chemoattract for these cells. However no
migration was observed with the mouse neutrophils. These cells have not been reported
to display chemoattractant properties with the /3-defensins but they do display migration
with other antimicrobial peptides, LL-37 (Yang et al., 2001) with an optimum
concentration of 10"5M and PR-39 (Huang et al., 1997) at a peak concentration of 0.5-2
pM.
An interesting property to note is that all three defensins tested here contain
varying numbers of cysteine residues yet still retain chemoattractant properties.
Previous studies with the /3-defensins show that the cysteine residues are essential for
chemoattractant activity. Studies with HBD3 whereby the cysteine residues were
replaced with oaminobutyric acid (Wu et al., 2003) gave no migration for both
monocytes and HEK293 cells expressing CCR6 at concentrations greater than 10000
ng/ml. Defrl contains 5 cysteines, 5YC contains 6 and Defrl leys contains 1 cysteine
residues and all three display chemoattractant properties against certain cell types. Also
Defrl is a mixture of dimeric isoforms yet 5YC conforms to the /3-defensin connectivity
and both induce migration although Defrl appears to induce a higher number of cells at
a value 10-fold less than that of 5YC and Defrl leys.
In order to assess ifDefrl, 5YC and Defrl 1 cys utilise the chemokine receptor 6
(CCR6) in the migration observed via chemotaxis, HEK293 cells expressing CCR6 were
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used. No migration was observed with Defrl, 5YC or Defrl leys suggesting these
peptides do not use CCR6 within this chemotaxis assay. Previous analysis with the /3-
defensins has displayed the importance of CCR6 in migration (Yang et al., 1999) with
this being highlighted as the receptor involved. However other studies have suggested
this is not the only receptor. HBD3 displays chemoattractant properties towards
monocytes, which do not express functional CCR6 therefore suggesting an additional
receptor is involved (Wu et al., 2003). No studies have currently revealed what this
receptor is. Other antimicrobial peptides utilise different receptors to that of the (3-
defensins. LL-37 has been shown to act through the Formyl Peptide Receptor-Like 1
(FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes
and T cells (Yang et al., 2000).
In summary, these results highlight that Defrl displays potent antimicrobial
activity against an array of pathogens. Being a mixture of different isoforms Defrl
HPLC fractions displayed similar antimicrobial properties and by mass spectrometry
were identical. The synthesis of Defrl leys emphasised that the dimeric structure was
essential for activity with this peptide and upon reduction the activity was lost.
Migration in response to Defrl, 5YC and Defrl leys was achieved despite a varying
number of cysteine residues. Importantly these peptides were shown not to induce
migration of HEK293 cells expressing CCR6. To date, this is the first example of a /?-
defensin failing to induce migration ofHEK293 CCR6 cells.
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CHAPTER 4:
Defbl4 THE MURINE ORTHOLOGUE OF
HUMAN /3-DEFENSIN 3
4.1 INTRODUCTION
Evolutionary analysis of the /3-defensin superfamily demonstrates that the murine
orthologue of the widely studied human /3-defensin 3 (HBD3) is Defbl4 (Semple et al.,
2005). This gene Defbl4, encodes a predicted peptide which is 68% identical to that of
HBD3 and notably displays only four amino acid changes that are not conserved or
semi-conserved. The second exon sequence of Defbl4 was first discovered by a
genomic approach (Schutte et al., 2002).
Human /3-defensin 3 (DEFB103) is a member of the /3-defensin multigene family
located in the major defensin locus on the human chromosome 8 (Garcia et al., 2001a,
Harder et al., 2001). HBD3 was initially identified in lesional psoriatic scales and was
subsequently cloned from foreskin derived keratinocytes and lung epithelial cells
(Harder et al., 2001). In additional studies HBD3 was cloned based on bioinformatics
and functional genomic analysis (Jia et al., 2001, Garcia et al., 2001a).
The isolation and purification of HBD3 from lesional psoriatic scales,
keratinocytes and lung epithelia revealed these as an effective source for the peptide.
Expression of HBD3 mRNA was detected predominantly in epithelial tissues but was
also found in non-epithelial sources. The skin, tonsils, gingival keratinocytes, skeletal
muscle, adult heart, testis and oesophagus are the major tissues expressing HBD3
(Harder et al., 2001, Jia et al., 2000, Garcia et al., 2001a). The induction of HBD3 has
become evident in HaCaT keratinocytes with the exposure to IFN-y giving rise to a 136-
fold increase in transcripts (Garcia et al., 2001a, Abiko et al., 2003). HBD3 has also
been show to be induced by bacterial stimulus. In a study with P.aeruginosa clinical
isolates and human primary keratinocytes, HBD3 was shown to be strongly expressed
(Harder et al., 2001).
The mature form of the HBD3 peptide consists of 45 amino acids and is a highly
basic antimicrobial peptide. Antimicrobial activity has been detected in synthetic,
recombinant and naturally occurring peptides. HBD3 displays potent broad spectrum
activity against Gram-negative bacteria, Gram-positive bacteria and fungi (Harder et al.,
2001, Garcia et al., 2001a, Sahly et al., 2003). Antimicrobial activity has been detected
against a wide range of pathogens. Minimal bactericidal values against S.aureus ATCC
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6538 give 1.5-6.3 gg/ml (Harder et al., 2001), S. epidermidis 1.6 gg/ml, E. coli 0.4
gg/ml, Acinetobacter sp 0.2-1.6 gg/ml (Sahly et al., 2003) and B. cenocepacia ATCC
17770 6.6pg/ml (Garcia et al., 2001). Subsequent studies regarding B. cenocepacia, B.
stabilis, B. vietnamiensis and B. multivorans have displayed high resistance (MBC value
>100 gg/ml) towards human /3-defensin 3 (Sahly et al., 2003). Multidrug-resistant
nosocomial strains have been evaluated against HBD3 giving MBC values of 4-8 pg/ml
against S. maltophilia, 4-8 gg/ml against S. aureus and 8 gg/ml against E. faecium
(Maisetta et al., 2006). Recently extended spectrum /3 -lactamase (ESBL)-producing
Klebsiella strains have been tested. Generally the strains show high susceptibility to
HBD3 with MBC values in the range of 3.12 - 25 pg/ml (Sahly et al., 2006). Further
studies have been conducted using HBD3 in combination with other antimicrobial
agents, lysozyme, metronidazole, amoxicillin and chlorohexidine against oral pathogens.
In combination the bactericidal activity of HBD3 was shown to be enhanced (Maisetta et
al., 2003). HBD3 has also demonstrated salt insensitive antimicrobial activity with S.
aureus ATCC 6538 (Harder et al., 2001). Against S. aureus HBD3 has been shown to
retain 90% killing at 250mM NaCl concentration.
The mechanism of HBD3 antimicrobial activity is not yet known. Like other /3-
defensins, it is believed that the antimicrobial action of HBD3 is based on electrostatic
interactions although this mechanism is poorly understood. The membrane activity of
HBD3 has been investigated using membrane lipid compositions, sensitive LPS strains
of S. enterica sv Minnesota R595, E. coli F515 and resistant P. mirabilis R45 isolates
(Bohling et al., 2006). This study has shown a clear correlation between the biological
activity of HBD3 and the interaction with the membrane lipid composition particularly
with the outer membrane lipids from sensitive bacterial strains. Ultrastructural studies
have been performed to develop an insight into the mechanisms by which HBD3 kills S.
aureus. Morphological changes were examined using transmission electron microscopy
and revealed signs of perforation of the peripheral cell wall, liberation of the plasma
membrane and bacteriolysis after two hours (Harder et al., 2001). Regarding
mammalian cell membranes numerous studies have been performed discussing the
hemolytic and cytotoxic properties of HBD3 (Kluver et al., 2005, Harder et al 2001).
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HBD3 was assessed for cytotoxic activity against human erythrocytes with no
significant hemolysis detected except when associated with high concentrations of
HBD3 (500jxg/mL)(Harder et al., 2001).
The /3-defensins have been shown to maintain a role in both the innate and
adaptive immune response. Many defensins including HBD3 act as chemoattractants at
nanomolar concentrations with activity against a variety of cell types. HBD3 has
induced migration ofmonocytes with a maximal response at lOOng/ml (Wu et al., 2003)
although no migration was evident with neutrophils (Garcia et al., 2001a). Migration
has been observed with CD4+ T cells and immature dendritic cells but not shown with
mature dendritic cells. CCR6 appears to be the chemokine receptor that the /3-defensins
seem to be acting through (Yang et al., 1999). Migration was observed with HEK293
cells transfected with CCR6 at an optimal concentration of lOng/ml. HBD3 has been
shown to be active against both the CCR6 chemokine receptor and another unidentified
receptor present on monocytes (Wu et al., 2003).
Structure activity relationships associated with HBD3 have been studied
extensively. Structural characteristics between several /3-defensins have confirmed the
disulfide connectivity observed within the family is (Cysl-Cys5, Cys2-Cys4, Cys3-
Cys6) (Ganz et al., 1999). Chemically synthesised analogues with predefined sulfide
connectivities have been created and tested for their antimicrobial and chemoattractant
properties. All analogues exhibited similar antimicrobial characteristics whereas various
chemoattractant properties were observed. Included in this analysis was native HBD3
which in vitro does not fold preferentially into the described native conformation (Wu et
al., 2003). Further analysis involved replacement of all the cysteine residues with a-
aminobutyric acid which rendered the peptide inactive chemotactically and yet enhanced
its antimicrobial properties (1 ug/ml against S. aureus) (Wu et al., 2003, Hoover et al.,
2003). Native disulfide linkages and non-native linkages, varying peptide sequence
lengths, hydrophobicities and net charges have been evaluated in an attempt to elucidate
the functional requirements (Wu et al., 2003, Hoover et al., 2003, Kluver et al., 2005).
This chapter describes the first documented study involving the characterisation
of Defbl4. Synthetic peptide preparations were evaluated in numerous experiments for
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functional analysis. A synthetic analogue, Defbl4 leys was analysed to elucidate a
connection between structural differences and functionality with that of the original
Defbl4 peptide preparation. In addition Defbl4 was synthesised whereby the cysteine
residues were replaced with alanine residues. This peptide was analysed for
antimicrobial and chemoattractant properties.
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AIMS
The aims of this chapter were to:
1 Characterise a synthetic preparation of Defbl4 the murine orthologue of
HBD3
2 Evaluate Defbl4 leys, a synthetic dimeric analogue ofDefbl4




A synthetic preparation of Defbl4 was examined in order to characterise the
antimicrobial and chemoattractant properties. To gain an understanding into the
structural requirements for functionality a further peptide, dimeric Defbl4 leys was
characterised. In addition to structure and function, the ability of these peptides to lyse
human erythrocytes was also evaluated.
4.3.1 Defbl4 is the orthologue to DEFB103 (HBD3)
Defbl4 is 68% identical to that of the HBD3 primary sequence (Table 4.1).
Only 4 amino acid changes have been noted that are not conserved or semi-conserved
within the sequence. Evolutionary analysis of the /3-defensin family demonstrates that
DEFB103 and Defbl4 are orthologues and that there is a complexity of selective
pressures acting on this gene family (Semple et al., 2005). Of the four non-conservative
changes, one lies between cysteine 4 and 5; one between cysteine 3 and 4; and two
located at the N-terminus of the peptide. At the N-terminus the sequences reveal a
change in a glycine from the HBD3 to a phenylalanine in the Defbl4 and a change in
isoleucine from the HBD3 to a proline in the Defbl4. Between cysteine 3 and 4 the
sequence displays a change in proline from the HBD3 to a glycine in the Defbl4. In
addition a change is observed between cystein 4 and 5 revealing a change from an
arginine in the HBD3 to a serine in Defbl4.
4.3.2 Expression of Defbl4
The expression of Defbl4 was assessed using various tissues from mice. RT-
PCR was performed and transcripts were detected in the trachea, oesophagus, and strong
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4.3.3 Gel electrophoresis of Defb 14
In order to determine the properties of the predicted mature Defb 14 peptide
encoded by exon 2, we synthesised the 45 amino acid peptide (Table 4.1).
Characterisation of the Defb 14 peptide on a 16% tricine gel revealed that the preparation
consisted of a less predominant upper band with a lower band around 7 kD in size
(Figure 4.2). The expected size of Defbl4 is 5184 kDa. In contrast, HBD3 has a very
different appearance with a lower band running around 5 kDa and additional abundant
species at ~ 10 kDa. Upon reduction, the upper band(s) alters in size to ~5 KDa
consistent with some significant structural alteration between the reduced form and the
oxidised form. To analyse the effect of oligomeric state of Defb 14 on its biological
properties we synthesised Defb 14 leys wherein all the cysteines were replaced with
alanine residues except from that at position 5 (Table 4.1). The majority (>95%) of
Defb 14 leys oxidised peptide migrates with an apparent mass of ~ 12 kDa (with a small
amount of peptide at ~5 kDa) and upon reduction, the major band appeared at 7 kDa.
4.3.4 Accurate mass analysis
Defb 14 and Defb 14 leys were analysed by ESI-MS to assess their aggregation
tendencies and high resolution ESI-FT-ICR mass spectrometry was used to determine
the oxidation states of Defb 14 and HBD3 (Performed and optimised by Bryan
McCullough). Figure 4.3 shows the ESI mass spectra of Defbl4 (top) and of Defbl4
leys (bottom) obtained from analysis on a Q-ToF MS (Micromass). Figure 4.4 shows
the isotopic envelopes obtained for the +6 charge states of Defb 14 (top) and HBD3
(bottom) following FT-ICR MS analysis. The open squares are the predicted isotopic
ditributions from the sequence of a fully oxidised peptide with three S-S bridges and the
closed squares are the predicted distribution of isotopes for a fully-reduced peptide. It is
clear that there is very good agreement between the theoretical and observed distribution
showing that both peptides are fully oxidised.
Defb 14 is monomelic whereby Defb 14 1 cys readily oxidised to form a dimer
with a single intramolecular disulfide bond shown by mass spectrometry (Figure 4.3
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corresponds to a fully oxidised peptide, which strongly implies that this is a disulfide
bridge dimer (data not shown). This was confirmed by CID (collsion-induced
dissociation) MS analysis (Perdita Barran personal communication); the peptide does
not dissociate into two monomers under these conditions suggesting a covalent
interaction. This is further confirmed by gel electrophoresis analysis that also reveals
structural alteration between the reduced and oxidised forms of this peptide.
4.3.5 Disulfide analysis
Following digestion and mass mapping, the S-S connectivities observed between
cysteines in Defbl4 and in HBD3 are shown in table 4.2 (a-c) (Performed and optimised
by Dr David Clarke). Table 4.2a represents peptides from a Defbl4 trypsin digest.
Sequences in brackets indicate the presence of S-S bonds either within the peptide (one
sequence) or between peptides (two sequences). Two major connectivities were
assigned Cysl-Cys4, Cys2-Cys3, Cys5-Cys6 and either Cysl-Cys4, Cys2- Cys5, Cys3-
Cys6 or Cysl-Cys4, Cys2-Cys6, Cys3-Cys5 (these were indistinguishable by mass
alone). Table 4.2b displays the peptides identified when one missed cleavage is taken
into account; this only shows evidence for the Cysl-Cys4, Cys2-Cys3, Cys5-Cys6
topology suggesting it is the most abundant connectivity. Table 4.2c displays the
identified fragments from a trypsin/chymotrypsin digestion of HBD3. Only the N-
terminus and the canonical Cys2-Cys4 peptide were able to be assigned.
4.3.6 NMR analysis
A comparison of the 1H 600 MHz spectra ofDefbl4 and HBD3 (Figure 4.5) was
performed and optimised by Dr Dusan Uhrin. Figure 4.5 shows large differences in the
spread of the 1H signals between the two peptides. Signals at both extremes of the
HBD3 spectrum are in agreement with the reported 1H chemical shifts for canonically
folded HBD3 (Schibli et al., 2002). With Defbl4 a much narrower range of NH,
aromatic and CH3 signals found for Defbl4 indicated that this fully oxidised peptide
with 3 S-S bonds, does not impose a unique and stable tertiary structure. Defbl4 was









1 FLPK 503.31 503.32
yum TLR 388.24 388.34
3 K 146.11 146.08
4+9 (FFC1R)(C4SNSGR) 1191.5 1191.45
5 IR 287.2 287.21
■m GGR 288.15 288.18
7 (C2AVLNC3LGK) 917.45 917.47
7+11 (C2AVLNC3LGK)(C5C6K) 1295.57 1295.86
8 EEQIGR 730.36 730.29
10 K 146.11 146.08
11 (C5C6K) 378.12 378.52
12 K 146.11 146.08
13 K 146.11 146.08








1+2 FLPKTLR 873.55 873.65
2+3 TLRK 516.35 516.97
3+4+9 (KFFC1R)(C4SNSGR) 1319.61 1319.96










1 GIINTL 629.37 629.42
8+11 (C2AVL)(C4STR) 388.24 388.34
Table 4.2 (a-c) Identified tryptic fragments of Defbl4 and HBD3
Table 4.2a displays the identified peptides from Defbl4 trypsin digest.
Table 4.2b displays the peptides identified when one missed cleavage is taken into
account.
Table 4.2c displays the identified fragments from a trypsin/chymotrypsin digestion of
HBD3.
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the characteristic three stranded /3-sheet core with a partly helical segment at the N-
terminus. Accurate mass analysis was performed before and after the NMR to rule out
protein reduction or degradation during the experiment.
4.3.7 Antimicrobial analysis of Defbl4 and Defbl4 leys
Antimicrobial analysis was performed on both Defbl4 and Defbl4 leys against a
panel of Gram positive and negative micro-organisms. Defbl4 displays potent
antimicrobial activity against a spectrum of organisms (Figure 4.6 - 4.12). The majority
of organisms gave MBC values with Defbl4 (Table 4.3). P.aeruginosa PAOl appeared
to be the most susceptible with an MBC value of 1.5 ug/ml (p<0.01) and B.cenocepacia
the most resistant with an MBC value greater than 100 jig/ml. Furthermore, the
activity of the single cysteine dimer form of the peptide (Defbl4 leys) displays similar
MBC values as the original Defbl4, P.aeruginosa PAOl 1.5 pg/ml (p<0.01) and yet
again high values against B.cenocepacia >100 pg/ml. Upon reduction with DTT no
change was evident in the MBC values from both the Defbl4 and Defbl4 leys (Table
4.3).
4.3.8 Evaluation of varying salt concentrations on antimicrobial activity
To identify the effect of NaCl on the antimicrobial activity of Defbl4 and
Defbl4 leys varying salt concentrations were evaluated (Table 4.4). Defbl4 and
Defbl4 leys were tested with S.aureus and P.aeruginosa against 50 mM to 250 mM
concentrations of NaCl. Both peptides displayed antimicrobial activity with S.aureus
but higher concentrations were required for killing at 250 mM. MBC values increase
from 3.13 ug/ml to 25 gg/ml at this salt concentration. In contrast the MBC values for
P.aeruginosa remained unaltered at 1.5 ug/ml for the full range of salt concentrations.
4.3.9 Evaluation of varying human serum concentrations on antimicrobial
activity
To identify the effect of human serum on the antimicrobial values of Defbl4 and
Defbl4 leys varying concentration of serum were evaluated. Pooled human serum was
100
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Figure 4.6 Antimicrobial activity of Defbl4 and Defbl4 leys againstA baumannii
ATCC 19606
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 4.7 Antimicrobial activity of Defbl4. Defbl4 leys and HBD3 against B.
cenocepacia J2315
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
































Figure 4.8 Antimicrobial activity ofDefbl4 and Defbl4 leys against E. coli ATCC
25922
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 4.9 Antimicrobial activity of Defbl4 and Defbl4 leys against E. faeca/is ATCC
700802
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number ofCFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 4.10 Antimicrobial activity ofDefbl4, Defbl4 leys and HBD3 against P.
aeruginosa PAQ1
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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Figure 4.11 Antimicrobial activity ofDefbl4. Defbl4 leys and HBD3 against S. aureus
ATCC 25923
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number ofCFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =

























Figure 4.12 Antimicrobial activity of Defbl4 and Defb14 leys against S. aureus MRSA
J2918
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number of CFU surviving in the peptide treated
sample as a percentage of the counts from the blank control sample. ** = p<0.01, * =
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used at concentrations of 0.1 %, 1 % and 10 %. Defbl4 and Defbl4 1 cys were
evaluated against P. aeruginosa PAOl at a peptide concentration of 50 pg/mL. In the
presence of 0.1 %, 1 % and 10 % serum the antimicrobial activity was significantly
potent (0.1 % (p<0.01), 1% (p<0.01) and 10 % (p<0.01) comparable with the 0 % serum
free control.
4.3.10 Chemoattractant analysis of Defbl4 and Defbl4 leys
Both Defbl4 and Defbl4 leys were evaluated for chemotactic activity against
neutrophils, monocytes, CD4+ T cells (human & mouse) and CCR6 expressing HEK293
cells (Figure 4.14-4.19). The Defbl4 parent monomeric molecule displays activity on
human monocytes (Table 4.5) at 1000 ng/ml (p<0.01) with the Defbl4 leys displaying
optimum activity at 100 ng/ml (p<0.01). Defbl4 and Defbl4 leys are also able to
chemoattract human and mouse CD4 T cells at 100 ng/ml (p<0.01) and 10 ng/ml
(p<0.01) respectively. Again the single cysteine dimer displays ten fold greater activity.
Figure 4.17 show that Defbl4, similar to HBD3 induces the chemotaxis of CCR6-
expressing HEK293 cells in a dose dependent manner with an optimal concentration of
100 ng/ml (p<0.01). Defbl4 and Defbl4 leys are equally active against the human
CCR6 receptor on the FIEK293 cells. No migration was observed from both the Defbl4
and DefbM leys against murine neutrophils (Figure 4.19).
4.3.11 Haemolytic activity of Defbl4 and Defbl4 leys
The haemolytic activity of DefbM and DefbM leys were evaluated against
human erythrocytes (Figure 4.20). A range of concentrations from 3.9 pg/ml to 500
pg/ml were tested with both DefbM and DefbM leys giving similar values observed
haemolysis taking place at concentrations above 250 pg/ml. In addition peptides
DefbM and DefbM leys treated with DTT were evaluated. Both the peptides gave








Figure 4.13 Antimicrobial activities ofDefbl4 against P. aeruginosa PAOl in the
presence of human serum
Bacteria were incubated with the peptide at 50pg/mL over a range ofhuman serum
percentages. Graph A and B shows the number of colony forming units (CFU) ±
standard error from the blank control and peptide treated samples. ** = p<0.01, * =
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Figure 4.14 Migration ofmouse CD4+ T cells in response to Defbl4 and Defbl4 leys
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts. Experiments were
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Figure 4.15 Migration of human CD4+ T cells in response to Defbl4 and Defbl4 leys
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts. Experiments were
repeated three times and the above is a representative experiment (n=3).





























□ CM ■ Deb14 □ Defb14 leys □ CCL20
□ CM ■ Defb14 □ Defb14 leys □ CCL20
Figure 4.16 Migration of CCR6 expressing HEK293 cells in response to Defbl4 and
Defbl4 leys
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts Experiments were
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Figure 4.17 Migration of CCR6 expressing HEK293 cells in response to Defbl4 and
HBD3
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts. Experiments were
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Figure 4.18 Migration of human monocytes in response to Defbl4 and Defbl4 leys
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts. Experiments were
repeated three times and the above is a representative experiment (n=3).
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Figure 4.19 Migration of neutrophils in response to Defbl4 and Defbl4 leys
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts. Experiments were
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Figure 4.20 Migration ofHEK293 cells in response to Defbl4. Defbl4 leys and HBD3
Graph A shows the mean number of cells migrated per random field of view. Graph B
shown the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the media alone sample. * represents p< 0.05, ** p<0.01.
Error bars represent the standard error of all nine replicate counts. Experiments were
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Figure 4.21 Lysis of human erythrocytes in the presence of Defbl4 and Defbl4 leys +/-
DTT
Graph A shows the haemolysis of human erythrocytes in the presence of Defbl4 and
DefbH 1 cys. Graph B shows the samples reduce with lOmM DTT
* represents p< 0.05, ** p<0.01 control vs peptide. Experiments were repeated three
times and the above is a representative experiment (n=3).
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4.3.12 Analyses ofDefbl4 all alanine
Defbl4 was synthesised whereby all the cysteine residues were replaced with
alanine residues (Figure 4.21). Antimicrobial analysis against P.aeruginosa, S.aureus
and B.cenocepacia displayed killing activity similar to that of the Defbl4 parent peptide.
Interestingly the chemoattractant properties with Defbl4 all alanine, were diminished






CELL TYPE Defbl4 all alanine
HEK293 >10000
HEK293 CCR6 ■■HI: >10000
Values represented as ng/ml. Highest test concentration 10000 ng/ml.
C)
ORGANISM Defbl4 all alanine Defbl4
B.cenocepacia J2315 >100 >100
P.aeuriginosa PAOl 1.5 1.5
S.aureus ATCC 25923 6.25 6.25
Highest test concentration 100 ug/ml
Figure 4.22 Defbl4 all alanine analyses
A) Sequence of Defbl4 all alanine
B) Chemotactic activity of Defbl4 all alanine
C) Antimicrobial analysis of Defbl4 all alanine
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4.4 DISCUSSION
Through evaluation of Defbl4 the murine orthologue of HBD3 and Defbl4 leys
the dimeric analogue, this study has shown the following:
• That Defbl4 is expressed in a variety of murine tissues.
• That synthetic oxidised Defbl4 is a mixture of monomeric species and
various non-canonical disulphide connectivities.
• That this non-canonical synthetic Defbl4 displayed both antimicrobial and
chemoattractant properties,
• That the synthetic dimeric analogue Defbl4 leys displays antimicrobial and
chemoattractant properties similar to that of the monomeric peptide.
• That Defbl4 and Defbl4 leys display similar haemolytic profiles
• That both Defbl4 and Defbl4 leys display salt insensitive activity regarding
P.aeruginosa.
4.41 Sequence analysis
The evolutionary analysis of Defbl4 demonstrated that this is the murine
orthologue of human /3-defensin 3 with 68% of the sequences being identical and only
four amino acids changes that are not conservative or semi-conservative (Semple et al.,
2005). Genes that are involved in host defence often display high rates of genomic
divergence and evidence for adaptive evolution which is thought to be a possible
response to the rapid evolution of pathogens. Evolution of HBD3 does not seem to have
encountered striking episodes of amino acid changes arising from positive selection
although other /3-defensins do show this. Interestingly of the four amino acid changes,
the rat orthologue (DEFB14) has the same amino acids as the mouse at three of these
positions, but the serine at position 36 in the mature peptide is a lysine in the rat and an
arginine in the human. This is not a position where any change is seen in a detailed
examination of the primate sequences (Boniotto et al., 2003). The two N-terminal non-
conservative differences between the human and mouse lie at the front of the predicted
alpha helix in a sequence and 3D structure alignment with HBD3. The change between
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cysteine 3 and 4 is a proline in HBD3 and a glycine in Defbl4 (Table 4.1). Proline
residues may be helpful in forming /3-hairpins (Krishnakumari et al., 2003) and is
conserved in the primate HBD3 sequences.
4.42 Structural characterisations
Comparing the structural characterisation of Defbl4 and Defbl4 leys was
accomplished by using a variety of analytic methods. Previous structural analyses of
HBD1, HBD2 and HBD3 (Schibli et al., 2002) was performed using the native gel
electrophoresis system that Defbl4, Defbl4 leys and HBD3 have been studied with
here. Using this method HBD1 and HBD2 were found to migrate on the gel with similar
mobilities, whereas HBD3 ran significantly slower. According to the size of the band it
can be deduced that the disulfide bonds are intact and the mobility indicates the presence
of a dimer. HBD1 and HBD2 migrate at the appropriate monomer expectation. Upon
reduction of the disulfide bonds with DTT, the mobility of all three of the defensins is
increased and their mobilities become more similar. This potentially indicated that the
tertiary structure of HBD3 is disrupted and results in a loss of the stable dimer structure
when the disulfide bonds are cleaved. Defbl4 leys is a dimer due to the covalent
disulfide-bridged linkage that was imposed, whereas HBD3 and Defbl4 look as though
they may have the ability to form dimers. However they may be forced to present a far
more hydrophobic structure to the native gel via their S-S bridges which would result in
a lower electrophoretic mobility. When the defensins are reduced, they are free to
reorganise their polypeptide chains and the hydrophobic groups will then group together
internally in the peptide structure. This will raise the mobility of the peptide through the
gel and could result in the differences seen here and those reported by Schibli et al.,
2002.
To determine the clear oxidation states of HBD3 and Defbl4 ESI-FT-ICR mass
spectrometry was performed concluding that both peptides are only observed as
monomers, despite their dimer like appearance on the gel. In contrast to previously
studied defensins, Defrl (Campopiano et al., 2004) and Defbl07 (McCullough
manuscript accepted 2006) no evidence was observed for higher order non-covalent
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aggregates for both Defbl4 and HBD3. Defbl4 and HBD3 was electrosprayed under a
variety of conditions, various concentrations, pHs and buffer concentrations, however no
peaks corresponding to the formation of a non-covalent dimer for either Defbl4 or
HBD3 was observed. This is perhaps not surprising considering the high number of
basic residues contained in these peptides; columbic repulsion will dictate that they will
not interact non specifically, and the findings imply that both Defbl4 and HBD3 possess
no particularly favoured specific interaction leading to dimerisation.
The /3-defensins are often classified due to their canonical cysteine backbone.
The a-defensins constitute a cysteine backbone with the connectivities cysl-cys6, cys2-
cys4, cys3-cys5 (Selsted et al., 1989). The typical canonical arrangement for the (3-
defensins is cysl-cys5, cys2-cys4, cys3-cys6. With Defbl4 no evidence was seen for
this /3-defensin bridging pattern. The dominant connectivities observed of cysl-cys2,
cys3-cys4, cys5-cys6 and cysl-cys4, cys2-cys5 and cys3-cys6 are previously
undescribed arrangements for defensins and will present an extended and disordered
conformation (confirmed by NMR analysis). The sterically unlikely cys5-cys6 bond has
previously been described in hepcidin, a four-disulfide amphipathic cationic peptide
made in the liver where it is believed to have functional significance (Hunter et al.,
2002). HBD3 does show some evidence for a canonical /3-defensin fold. For both
Defbl4 and HBD3 proteolytic digestion produced several unidentified peaks, and it is
possible that some conformers with connectivities other than those referred to in Table
4.2 are present in lower abundancies. Kluver et al., 2005, synthesised two HBD3
peptides with the disulfide pattern predicted for /3-defensins and resulted in significantly
different products. From the oxidative folding of the 45 residue peptide a major product
with the desired disulfide connectivity was found. The second peptide, a 40 residue with
the first five residues missing from the mature peptide sequence led to a mixture of fully
disulfide bonded isomers containing no significant amounts of the product with the /3-
defensin disulfides. Since both were performed under identical reaction conditions it is
possible that the first five residues of the peptide facilitate the formation of the /3-
defensin specific disulfide bonded pattern and are important sterically in the formation
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of a key intermediate. Although Wu et al., 2003 found that HBD3 did not fold
preferentially into a native conformation in vitro under various oxidative conditions.
Three dimensional structures of a number of defensins have been determined by
both NMR and x-ray crystallography (White et al., 1995). Regarding human /3-defensins
the first structure for HBD2 was reported using NMR (Schibli et al., 2002) and also for
x-ray crystallography (Hoover et al., 2000). Previous HBD3 analysis by Schibli et al
2002, was found to be in agreement with our preparation of HBD3. Signals at both
extremes of the HBD3 spectrum are in agreement with the reported chemical shifts for
canonically folded HBD3. HBD3 has been suggested to form a stable dimer through an
28 32intermolecular salt bridge between Glu on one monomer and Lys on another via a
symmetrical H-bond interaction between Gin29 of both monomers. The NMR work of
Schibli et al 2002 did not directly show this. This dimer formation will also rely on
intramolecular bridging between Glu27 and Arg17. The role of these residues was
recently explored by the study of a triple mutant, which replaced this putative
dimerisation motif. The mutant HBD3 was a monomer but found to be just as active as
the wild type HBD3 (Boniotto et al., 2003). Three of the four sites are conserved
32between human and mouse, but the fourth, Lys ~ has semi-conservatively changed in the
mouse sequence to an arginine. Analysis with ESI-MS revealed that there is no
evidence for dimer formation for HBD3 although its identifiable S-S connectivities are
consistent with /3-defensins. Schibli et al., 2002 also reported that HBD3 does not
appear as a dimer via ESI-MS although they do not specify the conditions employed.
This result is contrary to the experimental results obtained in solution by diffusion based
experiments (NMR) and light scattering which indicates that HBD3 is a dimer.
4.43 Antimicrobial analysis
Previous antimicrobial activity analysis of a five cysteine unique murine defensin
related peptide (Defrl) displayed antimicrobial activity in its dimeric form. This
activity was lost upon reduction of the peptide to a monomeric form (Campopiano et al.,
2004). In this specific case it was concluded that the antimicrobial activity of Defrl was
directly related to its tertiary structure. With Defbl4 antimicrobial activity assays were
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performed against a panel of Gram positive and Gram negative organisms. The six
cysteine murine orthologue of HBD3 revealed that its activity is comparable with that
reported for HBD3 (Harder et al., 2001, Wu et al., 2003, Boniotto et al., 2003). This
activity is not altered upon reduction with DTT and is therefore independent of disulfide
structure. When analysing the single cysteine dimeric analogue Defbl4 leys, this
displayed the same minimum bactericidal concentrations (MBC) values as the original
Defbl4. This activity is not lost when the dimer is reduced to a monomer using DTT.
The Defbl4 all alanine peptide was also shown to be antimicrobial yet contained no
cysteine residues. Despite synthetic Defbl4 having a disordered structure with a mix of
novel disulfide connectivities it is still an effective antimicrobial and comparable with
the human orthologue HBD3. This work contradicts the Defrl study but is in agreement
with Wu et al., 2003 the cysteine bonding is not relevant to this activity. Further studies
to validate the irrelevance of cysteines for antimicrobial activities include a completely
linear preparation of synthetic HBD3 (Hoover et al., 2003). All the cysteine residues
were removed and replaced with a-aminobutyric acid creating a peptide which showed
the highest activity against E.coli and S.aureus.
The antimicrobial activity of Defbl4 and Defbl4 leys was analysed in the
presence of 0.1 %, 1 % and 10 % serum. Both peptides displayed killing under these
conditions although at 10% serum 100% killing was unattainable. Several studies have
displayed an activity decreasing effect with the presence of divalent cations (Tomita et
al., 2000, Hoover et al., 2003, Kluver et al., 2005). The divalent cations are thought to
compete with the peptides for the binding sites on the negatively charged bacterial cell
wall therefore only peptides with a higher net charge can access the cell surface. The
antimicrobial activity of both Defbl4 and Defbl4 1 cys was evaluated at various salt
concentrations. Defbl4 and Defbl4 leys remained unaffected when tested in this range
against P.aeruginosa PAOl. When tested against S.aureus ATCC 25923 in this assay a
higher concentration of the peptides was required for killing at 250mM. Harder et al.,
2001 tested HBD3 against S.aureus ATCC 6538 and concluded that activity declined in
the presence of 250 mM NaCl. HBD3 has also been tested in the presence of 100 mM
and 500 mM NaCl against A.actinomycetemcomitans and S.mutans. At 100 mM both
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these organisms remained unaffected when tested with HBD3. In contrast the ability of
HBD1 and HBD2 to kill was reduced (Ouhara et al., 2005). In 500 mM NaCl all the
peptides showed inhibition of antibacterial activity.
4.4.5 Chemotactic analysis
Chemotactic activity has been displayed in a variety of defensins including
HBD3. Activity has been detected against human monocytes at a migratory index of 2.0
(Garcia et al., 2001a). Chemotactic activity has also been identified with immature
dendritic cells (Yang et al., 2002) but not with mature dendritic cells. The chemotactic
activity of HBD1, HBD2 and HBD3 for immature dendritic cells is mediated by the
chemokine receptor CCR6 (Yang et al., 1999). The chemotactic activity of HBD3 to
monocytes must use another receptor other than CCR6 because monocytes do not
express functional CCR6. The monomeric Defbl4 displays poor activity against
monocytes. This is perhaps expected because the preparation appeared to be a mix of
analogues all without the canonical disulfide binding. The Defbl4 leys activity against
monocytes (optimal concentration lOOng/ml) is as potent as that reported for the
canonical form of HBD3 (Wu et al., 2003) despite being a mouse derived peptide
interacting with a human receptor. This implies that the structure directed by
intramolecular S-S binding is not essential for the defensin induced chemotactic
response of monocytes. Both Defbl4 and Defbl4 leys are equally active against
HEK293 cells expressing CCR6 and this activity is equivalent to that of our synthetic
canonically bound HBD3 and is equivalent and equal to that which we observe with
CCL20/MIP-3O! (the only chemokine known to interact with the CCR6 (Schutyser et al.,
2003). This again implies that the canonical bonding is not essential for the chemotactic
activity for Defbl4 although the Defbl4 all alanine peptide displayed no chemotactic
properties against HEK293 CCR6. Comparison of the crystal structure of CCL20 and
HBD1 and HBD2 has revealed some structural similarities despite no sequence
similarity (Hoover et al.,2002). An Asp4-Leu9 motif in HBD2, which resembles the
5 8*
Asp -Leu motif of CCL20/MIP-3o: is considered to be responsible for specific
interaction with CCR6, providing a structural basis for the capacity of /3-defensins and
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CCL20/MIP-3a: to interact with the same receptor. This region flanks the first cysteine
and yet Defbl4 leys without a cysteine at this first position is still active in attracting
CCR6 expressing cells.
4.45 Haemolytic profile
The interaction of /3-defensins with eukaryotic membranes is not well
understood. HBD3 has been shown not to exhibit significant lytic activity on human
erythrocytes (Harder et al., 2001) between 0 - 500 pg/ml. Defbl4 and Defbl4 leys gave
similar profiles against human erythrocytes with no significant lytic activity observed.
Generally it is assumed that the larger the number of hydrophobic amino acids leads to
an increased haemolytic activity with erythrocytes. Eukaryotic cell membranes consist
mainly of zwitterionic phosphatidylcholine and phosphatidylethanlamine susceptible to
hydrophobic interactions (Yeaman et al., 2003). Kluver et al 2005 described differences
in sequence of the HBD3 peptide responsible for haemolysis rather than the disulfides.
In summary, these results highlight that despite synthetic oxidised Defbl4 being
a mixture of monomelic species and various non-canonical disulfide connectivities,
antimicrobial and chemotactic properties are still observed. In addition the dimeric
analogue with only one cysteine residue displays equivalent antimicrobial and






During the past century antimicrobial agents have become a necessity in
combating infections previously considered life threatening. However the past decade
has seen infections considered curable returning with the ability to defy established
antimicrobials. Existing established agents have provided accurate protection and often
act as a template for the development of analogues within the family. Improvements in
efficacy, solubility, toxicity and cost have contributed to the success and exploitation of
these properties.
Established antimicrobials have been modified in an attempt to optimise the
desirable properties and importantly evade problems with resistance. Previously it was
very common to generate active analogues of existing antimicrobials in hope that there
would always be a backup ready if problems were encountered. Unfortunately this has
become increasingly difficult, few antimicrobials are being approved and new classes
are virtually unheard of. Recently tigecycline, a member of a new class of antimicrobial
agents, the glycyclines, was approved for treatment (Bosso et al., 2005) against
complicated skin infections. The glycyclines are derivatives of the tetracycline and
overcome the existing problems that these agents have previously encountered (Fraise et
al., 2006) with resistance.
The use of peptides of the innate immune system as therapeutic anti-infectives
has attracted a lot of commercial research. Various companies have been established to
pursue a new generation of peptide antimicrobials. Intrabiotics Inc was based on the
discovery of porcine leukocyte protegrins (Kokryakov et al., 1993) and their ability to
exhibit broad spectrum antimicrobial activity, low emergence of resistance and the
ability to maintain their activity in saliva. Disappointingly these peptides failed to
display any clinical advantage at Phase III trials. Helix Biomedix Inc focuses on a
diverse array of peptides including the polyphemusins, cecropins and melittins. They
aim to exploit the both the antimicrobial and modulatory properties of these peptides.
Current successes include potential therapeutic peptides HBCM2 and HBCM3 which
display potent in vitro and in vivo activity (Zhang et al., 2005). Micrologix Biotech Inc
has developed analogues to indolicidin isolated from bovine neutrophils (Selsted et al.,
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1992). Efforts have been concentrated on the development of topical application for
skin disorders and infections. Recently the discovery of plectasin, the first defensin to
be isolated from a fungus Pseudoplectania nigrella (Mygind et al., 2005) by Novazymes
has been encouraging. Plectasin displays extremely low toxicity in mice and has cured
peritonitis and pneumonia caused by S.pneumoniae as efficiently as penicillin and
vancomycin.
The antimicrobial peptide families are ideal candidates for therapeuctic agents
and functional derivatives have displayed attractive properties. Derivatives of
dermaseptin S4 have displayed improved toxicity profiles and desirable antimicrobial
values by altering the composition ofhydrophobic domains, reducing the hydrophobicity
and by increasing the net positive charge (Navon-Venezia et al., 2002). Completely
synthetic peptides, similar to that of naturally occurring peptides like tracheal
antimicrobial peptide, defensins and magainins have been studied for their activity
against multidrug-resistant cystic fibrosis pathogens (Schwab et al., 1999). Under
optimal conditions these peptides have been shown to be highly potent against multi¬
drug resistant pathogens, including mucoid P.aeruginosa and MRSA. Libraries of LL-
37 derived synthetic peptides have been generated and their anti-infective properties and
host stimulatory properties were evaluated (Braff et al., 2005). Synthetic peptides with
the first six and seven residues missing from the complete LL-37 gave lower MIC values
against the panel of organisms tested.
Regarding the /3-defensins active analogues have been generated from the
sequence of HBD1, HBD2 and HBD3 (Krishnakumari et al., 2006). These peptides,
based on the C-terminus of the original defensins have displayed activity against E.coli
(15-17 pM) and S.aureus (17-20 pM). HBD3 has been subject to several derivative
studies (Wu et al., 2003, Hoover et al., 2003 and Kluver et al., 2005) with various
regions of the peptide being of interest. Synthetic peptides have been generated at both
the N-terminus and C-terminus of HBD3. Variations in the number of residues, the
overall net charge and the hydrophobicity have been studied for their impact on
antimicrobial activity.
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This chapter describes the first documented study involving synthetic Defbl4
fragments. Peptide fragments were prepared and analysed to aid in identifying
antimicrobially active sequences. Further to this, experiments were performed for
functional analyses including chemotaxis, haemolysis and salt sensitivity.
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AIMS
The aims of this chapter were to:
1 Determine the activity of synthetic Defbl4 fragments
2 Determine whether the antimicrobial activity could be attributed to a
specific region of the mature Defbl4 peptide
3 Evaluate the activity of the Defbl4 fragments as chemoattractants




Synthetic fragments of Defbl4 were prepared and analysed to elucidate their
antimicrobial and chemoattractant properties. Defbl4 fragments were created based on
the original sequence with the cysteine residues replaced with alanine residues
(Maemoto et al., 2004). In total seven fragments were created and analysed for
functionally active sequences.
5.3.1 Synthetic preparations of Defbl4 fragments
Synthetic Defbl4 fragments were created in an attempt to locate functionally
active regions associated with the Defbl4 sequence. Initially the Defbl4 all alanine
peptide sequence was halved and both the N-terminus and C-terminus fragments were
created (Figure 5.1). A further change to the C-terminus involved replacing one alanine
residue with a cysteine residue to enable analyses of a potential dimeric formation.
Subsequent analyses concentrated on the N-terminus with a further three fragments
created to identify residues essential for antimicrobial activity. In addition a fragment
which overlapped both the N-terminal and C-terminal half was synthesised. The net
charge of the fragments ranged from +6 to +2 with the original Defbl4 peptide being
+12. The hydrophobicities of the fragments ranged from -1.62 to -12.35 with the
original Defbl4 at -12.65 (Table 5.1).
5.3.2 Antimicrobial analysis of Defensin inspired peptides 1-7
Antimicrobial analysis was performed on all the Defbl4 inspired peptide
fragments against a panel ofGram positive and Gram negative organisms. Dip 1, 4 and
5 display potent antimicrobial activity against a spectrum of organisms (Figure 5.2-5.9).
Interestingly the initial N-terminal fragment of Defbl4, Dip 1 gave potent antimicrobial
activity with MBC values of 3.13 pg/ml (p<0.01), 1.5 jug/ml (p<0.01) and 3.13 pg/ml
(p<0.01) against E.coli, P.aeruginosa and S.aureus (Table 5.2). These values are
identical to those of the Defbl4 parent sequence. Analysis of the C-terminus with Dip 2
and 3, concluded poor activity with MBC values greater than 50 pg/ml. Dip 3 included
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Figure 5.2 Antimicrobial activity ofDip 1, 2 & 3 against B.cenocepacia J2315
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number of CFU surviving in the peptide treated sample
as a percentage of the counts from the blank control sample. ** = p<0.01, * = p<0.05.
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■ Dip4 • Dip5 Dip6
Figure 5.3 Antimicrobial activity of Dip 4, 5 & 6 against B.cenocepacia J2315
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number ofCFU surviving in the peptide treated sample
as a percentage of the counts from the blank control sample. ** = p<0.01, * = p<0.05.








♦ Dip1 ■ Dip2 Dip3
Figure 5.4 Antimicrobial activity of Dip 1, 2 & 3 against E.coli ATCC 25922
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number ofCFU surviving in the peptide treated sample
as a percentage of the counts from the blank control sample. ** = p<0.01, * = p<0.05.
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Figure 5.5 Antimicrobial activity of Dip 4, 5 & 6 against E.faecalis ATCC 700802
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number of CFU surviving in the peptide treated sample
as a percentage of the counts from the blank control sample. ** = p<0.01, * = p<0.05.
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Figure 5.6 Antimicrobial activity ofDip 1, 2 & 3 against P.aeruginosa PAOl
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number of CFU surviving in the peptide treated sample
as a percentage of the counts from the blank control sample. ** = p<0.01, * = p<0.05.
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Figure 5.7 Antimicrobial activity ofDip 4, 5, 6 & 7 against P.aeruginosa PAQ1
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number of CFU surviving in the peptide treated sample
as a percentage of the counts from the blank control sample. ** = p<0.01, * = p<0.05.
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Dip1 ■ Dip2 Dip3
Figure 5.8 Antimicrobial activity of Dip 1, 2 & 3 against S.aureus ATCC 25923
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number of CFU surviving in the peptide treated sample
as a percentage of the counts from the blank control sample. ** = p<0.01, * = p<0.05.
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Figure 5.9 Antimicrobial activity of Dip 4, 5, 6 & 7 against S.aureus ATCC 25923
Graph A shows the number of colony forming units (CFU) ± standard error from the
blank control and the peptide treated samples. Graph B shows the mean percentage kill;
this is assessed by calculating the number ofCFU surviving in the peptide treated sample
as a percentage of the counts from the blank control sample. ** = p<0.01, * = p<0.05.
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a change from an alanine to a cysteine at position 5 (of the original Defbl4 sequence).
Both the C-terminal peptides Dip 2 and 3 gave similar values. Further analysis on the
N-terminus to identify antimicrobially active sequences was conducted (Table 5.2). Dip
4, 5 and 6 were synthesised to focus on the N-terminal half. Dip 4 and 5 gave similar
values, 25 pg/ml (p<0.01), and 1.5 pg/ml (p<0.01) against E.faecalis and P.aeruginosa.
An antimicrobial difference was detected with S.aureus with Dip 4 giving 50 pg/ml
(p<0.01) and Dip 5 at 12 pg/ml (p<0.01). Dip 6 displayed no MBC values at
concentrations less than 50 pg/ml against any of the organisms tested. This peptide
focuses on the peptide sequence furthest from the N-terminus but still retained within the
first half of the peptide. The sequence of Dip 7 was created to analyse an overlap of
both the N-terminal and C-terminal half. This peptide gave no MBC value below 50
pg/ml against P.aeruginosa and S. aureus. However Dip7 carries a net charge of +2 and
hydrophobicity of -7.64.
5.3.3 Evaluation of varying salt concentrations on antimicrobial activity
To identify the effect of NaCl on the antimicrobial activity of Dip 1, 4, and 5
varying salt concentrations were evaluated (Table 5.3). P.aeruginosa was tested against
these peptides in the presence of 50 mM to 250 mM concentration of NaCl. All Dips
tested gave MBC values at 1.5pg/ml against P.aeruginosa in varying salt concentrations.
No changes in MBC values were detected from any of the Dips at any of the salt
concentrations. The values remained the same.
5.3.4 Evaluation of varying human serum concentrations on antimicrobial
activity
To identify the effect of human serum on the antimicrobial values of Dipl
varying concentrations of serum were evaluated against P.aeruginosa PAOl (Figure
5.10). Pooled human serum was used at concentrations 0.1 %, 1 % and 10 %. Dip 1
still maintained its antimicrobial properties within the presence of serum (0.1 %
(p<0.01), 1 % (p<0.01) and 10 % p<0.01) compared to the 0 % serum free control.. At













































Figure 5.10 Antimicrobial activity of Dip 1 against P.aeruginosa PAOl in the presence
of human serum
Bacteria were incubated with the peptide at 50 pg/mL over a range ofhuman serum
percentages. Graph A shows the number of colony forming units (CFU) ± standard error
from the blank control and the peptide treated samples ** = p<0.01, * = p<0.05.
Experiments were repeated three times and the above is a representative experiment
(n=3).
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5.3.5 Chemoattractant analysis of Defbl4 inspired peptide fragments
The chemoattractant properties of Dip 1, 2 and 3 were evaluated using HEK293
cells expressing CCR6 (Figure 5.11). No migration was observed from any of the Dips
tested at the varying concentrations. The control chemokine, CCL20 / MIP3o: induced
migration at around 120 cells. The Dips concluded no migratory properties at the
concentrations tested against this cell type.
5.3.6 Hemolytic activity of Defbl4 inspired peptides fragments
The haemolytic activity of Dip 1, 2 and 3 were evaluated against human
erythrocytes in (Figure 5.12). A range of concentrations from 3.9 pg/ml to 500 pg/ml
were tested for all Dip 1, 2 and 3 all giving similar values. At the highest concentration
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Figure 5.11 Migration ofCCR6 expressing HEK293 cells in response to Dip 1, 2 & 3
Graph A shows the mean number of cells migrated per field of view from a total of nine
random fields. Graph B shows the migratory index, the number of cells migrated in each
sample divided by the number of migrated cells in the media alone sample. * represents
p<0.05, ** p<0.01. Error bars represent the standard error of all nine replicate counts.



















■Dip1 •Dip2 Dip3 TSB Tween-20
Figure 5.12 Lysis of human erythrocytes in the presence of Dip 1, 2 & 3
Graph A shows the haemolysis of human erythrocytes in the presence of Dip 1, 2 and 3.
Tween-20 positive control, TSB negative control. ** = p<0.01, * = p<0.05 control vs




Through evaluation of the Defbl4 inspired peptides, this study has shown the
following:
• That fragments associated closely with the N-terminus, Dip 1, 4 and 5
display potent antimicrobial activity comparable with that of the full
parent Defbl4 peptide sequence
• That peptides associated with the C-terminus, Dip 2 and 3, display no
antibacterial activity at the concentrations tested
• That Defbl4 inspired peptide fragments are not chemotactic with
HEK293 CCR6 cells at the concentrations tested
• That Dip 1, 2 and 3 display similar haemolytic profiles despite
differences in hydrophobicity
• That Dip 1 displays similar salt insensitive antimicrobial activity to that
of the parent Defbl4 regarding P.aeruginosa.
5.4.1 Antimicrobial analysis of Defbl4 inspired peptides
In order to dissect the antimicrobial activity of Defbl4 three initial fragments
were created Dip 1, 2 and 3. Dip 1, the N-terminal 23mer has no cysteine residues and
carries a net charge of +6 alongside the two C-terminal (22mer) fragments (Dip 2 & 3).
In comparison with the parent molecule, Defbl4 (+12), this charge is strongly reduced.
Antimicrobial activity is only exhibited with Dip 1 the N-terminal fragment and not
displayed with the C-terminal (Dip 2 & 3) peptide fragments. The hydrophobicities of
the C-terminal fragments Dip 2 & 3 are very similar to that of the parent molecule
(-11.54) (Table 5.1) however the hydrophobicity ofDip 1 is markedly increased (-1.62).
Since the N-terminal fragment Dip 1 is active against bacteria and the net
charge of the peptide fragments do not vary the differences in hydrophobicity may
propose a difference. Previous work on HBD3 (Kluver et al., 2005) discusses that
increasing the net charge and the hydrophobicity will increase the antimicrobial activity.
Peptides with less cationic residues and moderate hydrophobicity are virtually inactive
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whereas peptides with a high net charge and significant hydrophobic character are
active. Regarding Dip 1 this exhibited potent killing at the concentrations tested.
Concerning HBD3, the human orthologue of Defbl4, various studies have been
conducted regarding altering sequences and creating derivatives (Hoover et al., 2003,
Wu et al., 2003, Kluver et al., 2005, Krishnakumari et al., 2006). The N-terminus
sequence of HBD3 has been synthesised containing 17 residues and possessing a net
charge of only +4 (Hoover et al., 2003). This peptide has displayed antimicrobial
activity against both Gram positive and negative organisms in agreement with Dip 1.
Dip 1 display a net charge of +6 and contains five more hydrophobic residues than this
peptide but is also six residues longer.
Further analysis of the Defbl4 N-terminus initiated the synthesis of a further
three defensin inspired peptides in hope to identify active fragments. Dip 4 (lOmer), 5
(12mer) and 6 (lOmer) were synthesised giving net charges of +3, +5 and +2
respectively. Antimicrobial activity was detected with both Dip 4 and 5 but not with
Dip 6. Dip 7 was created without the first twelve amino acids and the last eleven amino
acids of the sequence and displayed no activity against the pathogens tested. Dip 4 and
Dip 5 possess activity and have a similar number of hydrophobic residues and net
charge. Dip 6 displays no killing at the concentrations tested but does remain furthest
from the start of the N-terminus sequence. This peptide also contains double the
hydrophobic residues (6) and carries a low net charge (+2). Previous studies have
shown when using N-terminal deletion mutants that the initial seven residues are
important for activity against gram positive organisms (Hoover et al., 2003). Dip 4 and
5 possess activity against S.aureus but display higher values than those required for Dip
1. Dip 5 must be brought to attention as this sequence has lost the first five residues
from the N-terminus but yet still displays activity against Gram positive organisms. Dip
6 has lost the first thirteen residues from the N-terminus and this may be important in the
lack of activity at the concentrations tested.
An a-helix is often present in the N-terminal stretch of full length oxidised /3-
defensins (HBD1-3). N-terminal regions of defensins are often more aliphatic, and since
helices are a frequent motif in antimicrobial peptides this has been postulated to be the
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region of the peptide which directs membrane insertion and disruption. It is also
interesting to note that Dipl, 6 and 7 contains a sequence of eight amino acids
(GGRAAVLN) which are identical to that of the XT4 peptide fragment of an
antimicrobial peptide isolated from the skin secretions of the diploid frog (Ali et al
2001). However this 22mer peptide is only active against Gram negative bacteria where
Dipl is active against Gram positive and negative organisms (charge +6, hydrophobicity
-1.62) and Dip 6 and 7 display no activity at the concentrations tested (+2, -2.08; +2,
-7.64).
The C-terminus of HBD3 has also been studied extensively. Derivatives of the
last ten residues of the peptide sequence have been created. This peptide carries a net
charge of +6 and consists of ten residues none of which are hydrophobic. Antimicrobial
activity was detected against Gram negative organisms but no activity was evident
against Gram positive organisms at the concetrations tested (Hoover et al., 2003). In
contrast Dip 2 and Dip 3 focus on the C-terminus of Defbl4 and display no
antimicrobial action against any of the organisms tested. These two peptides contain
five and four hydrophobic residues possess the same net charge of +6 and contain 22
residues. Dip 3 contains a cysteine residue in place of one of the alanine residues. This
was added to allow the peptide to form a dimer although by mass spectrometry this was
not the case as only the presence of a monomer was detected. Oxidation and folding
will need to be performed to allow the formation of a dimer. No peptides in the Hoover
study were similar in residue number, net charge and hydrophobicity to Dip 2 and Dip 3.
This may account for the differences observed in activity although the closest in length
was 20 residues with a net charge of +7. This gave no difference in antimicrobial
activity to that of the peptide containing only ten of the residues.
5.4.2 Antimicrobial activity in the presence of salt and serum concentrations
The antimicrobial activity of Dip 1, 4 and 5 were evaluated at various salt
concentrations. The defensin inspired peptides remained unaffected when tested in this
range against P.aeruginosa PAOl. No other organisms were tested. Studies involving
derivatives of HBD3 particularly the C-terminus (Hoover et al., 2003), show that
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antimicrobial activity is completely diminished at 150 mM NaCl against E.coli. The N-
terminal fragment of HBD3 displayed no measurable antimicrobial activity at the
concentrations tested at 150 mM against both E.coli and S.aureus.
Dip 1 at 50 pg/mL was tested in the presence of 0.1%, 1% and 10% human
serum. Dip displayed killing activity at the serum concentrations tested although at 10
% complete killing was not observed. In the same Hoover study the N and C-terminal
fragments were tested for activity in the presence of 1 mM Mg and 2 mM Ca. Yet again
no detectable activity was found against E.coli and S.aureus for N-terminal fragment.
The C-terminal fragment was tested against just E.coli in the presence of the same 1 mM
Mg and 2 mM Ca and displayed no measurable activity within the concentrations tested.
HBD3 derivatives of the N-terminus where in one peptide the cysteines are replaced
with alanine residues and in the other the cysteines are replaced with tryptophan residues
(Kluver et al., 2006) were tested for activity in the presence of Mueller-Hinton broth.
Antimicrobial activity appeared to diminish in the presence of a quarter Mueller-Hinton
broth. Both the N-terminal peptides contained 17 residues with the initial five residues
of HBD3 removed completely. The C-terminal peptides in the same study contained 27
residues and displayed the same diminished activity in broth containing a quarter
Mueller-Hinton.
5.4.3 Chemoattractant analysis
Chemotactic activity was evaluated with the initial three defensin inspired
peptides. HEK293 cells transfected with CCR6 were used in the assay against Dip 1, 2
and 3. No migration was observed using the concentrations tested against this cell type.
The disulfide connectivities have previously been reported to be essential for the
receptor binding and interaction (Wu et al., 2003). In this study the full length HBD3
was tested whereby the cysteine residues were replaced with aminobutyric acid, giving a
completely linear peptide devoid of all disulfides. This peptide displayed no
chemoattractant properties against the cell types tested. Monocytes and HEK293 CCR6
cells were inactive at concentrations less than 10000 ng/ml. Regarding the defensin
inspired peptides no other cell types were tested and this should be evaluated before
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completely concluding that no chemoattractant properties were observed. In the
previous chapter Defbl4 leys was tested for chemoattractant properties. This peptide
contained only one cysteine residue from the six cysteine backbone. This peptide
displayed chemoattractant properties with monocytes at 1000 ng/ml and HEK293 CCR6
at 100 ng/ml. Importantly this peptide does not contain the proposed Asp4-Leu9 motif
found in HBD2, which resembles the Asp5-Leu8 motif of CCL20/MIP-3o; considered
responsible for specific interaction with CCR6 (Hoover et al., 2002). This motif is also
not displayed in Dip 1, 2 and 3 as the cysteine residues are all replaced with alanine
residues.
5.4.4 Haemolytic properties
The haemolytic profiles of Dip 1, 2 and 3 were evaluated. All three defensin
inspired peptides gave similar haemolytic profiles which were also consistant with those
of the full peptide and the one cysteine variant in the previous chapter. The net charge of
Dip 1, 2 and 3 are all + 6 with the hydrophobicity of Dip 2 and 3 very similar (Table
5.1). Dip 1 gave an increased hydrophobicity but all three peptides displayed similar
haemolysis and no cytotoxic properties were observed below 250 pg/ml. The
haemolytic activity of HBD3 has been studied extensively (Kluver et al., 2005). This
research infers that a greater hydrophobicity encourages cytotoxic effects. Peptides with
moderate hydrophobicity are relatively inactive and peptides displaying high net charge
and hydrophobic properties are cytotoxic. This study does not display the haemolytic
results of the N-terminal and C-terminal peptides created whereby the cysteine residues
are replace with both alanines and tryptophan residues.
In summary, these results highlight that Dip 1, 4 and 5 which are based on the N-
terminus sequence of Defbl4 display potent antimicrobial properties similar to those of
the parent Defbl4 and Defbl4 1 cys. In addition all the defensin inspired peptides
displayed no chemoattractant properties against cells expressing CCR6. This in turn is




SUMMARY AND FUTURE STUDIES
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6.1 SUMMARY
A major hurdle for established antimicrobials has been the recent inability to
combat multiple drug resistant organisms. Antimicrobials are currently failing to control
or eliminate resistant infections. Addressing this problem would greatly improve the life
span and decrease costs of treatment. New targets and classes of antimicrobials are
required to help alleviate the problem.
Antimicrobial peptides are important components of the immune system's ability
to fight disease. They are widely distributed throughout the animal and plant kingdom
and rapidly inhibit infection. In numerous cases these peptides provide additional roles
acting upon the immune system to coordinate a protective response. The /3-defensins
display antimicrobial properties and chemoattractant roles within host defence.
In this thesis murine jS-defensins and defensins inspired peptides were analysed
for functional significance. Initial studies focused on a novel five cysteine defensin
related peptide termed Defrl. The work in this thesis showed that Defrl displayed
potent antimicrobial activity against a variety of pathogens including multi-resistant
isolates and 5YC, the six cysteine analogue, displayed poorer activity. However the
MBC values were not as low as established antimicrobials and the isolates were not
tested in the presence of varying salt conditions. Defrl has been shown to be a covalent
dimer containing an intermolecular disulfide bond and is a mixture of dimeric isoforms,
varying in intra and inter-molecular disulfide connectivities (Campopiano et al., 2004).
5YC forms a non-covalently bound dimer displaying the characteristic /3-defensin
connectivity. In an attempt to study the isoforms of Defrl, HPLC fractions were
collected at various time points and analysed by mass spectrometry, gel electrophoresis
and antimicrobial function. All fractions revealed similar profiles antimicrobially and
consisted of a mixture of isoforms like that of the original Defrl. Antimicrobial activity
was also abolished when HPLC fractions were treated with DTT. To confirm the
activity of a single dimeric species Defrl leys was created. This thesis showed that
Defrl leys has a similar antimicrobial profile to that of the original Defrl. Defrl leys
was also a dimer but was a single species and again upon reduction the antimicrobial
activity was diminished like that of the mixed isoform Defrl. Chemoattractant analysis
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of Defrl, 5YC and Defrl leys discovered that all three displayed migratory properties
with CD4+ T cells. Interestingly this thesis showed that not all cysteine residues were
required for this to be displayed although all were dimeric. This thesis also reported that
all three peptides did not display migratory properties with HEK293 cells transfected
with CCR6, the proposed receptor for the /3-defensins. This is currently the first report
of a /3-defensin not using CCR6 although additional receptors have been suggested for
HBD3 (Wu et al., 2003).
This thesis is the first functional report regarding Defbl4 the murine orthologue
of human /3-dcfensin 3. Defbl4 was synthesised and displayed potent antimicrobial
properties, similar to those experienced with the orthologue HBD3. In addition this
activity, in contrast to Defrl was not diminished in the presence of DTT. Defbl4 was
shown to be monomeric and a mixture of different disulfide connectivities therefore a
one cysteine dimeric variant was synthesised. This peptide displayed antimicrobial
properties similar to that of the original monomeric Defbl4. Chemotactic analysis
revealed that Defbl4 and Defbl4 leys displayed migratory properties for CD4+ T cells
and HEK293 CCR6 transfected cells again showing that the six cysteine residues are not
required for chemotactic activity in vitro. Monocytes were also attracted to Defbl4 and
these do not express a functional CCR6. This is comparable with experiments done with
HBD3 where similar properties are observed with chemotaxis.
The Defbl4 inspired peptides (Dips) provided an insight into drug design and the
regions of the peptide required to produce activity. Peptides based on the C-terminus
sequence displayed no antimicrobial properties but peptides based on the sequence of
the N-terminus did. Interestingly smaller N-terminal fractions continued to provide
antimicrobial activity. These peptide fragments have highlighted regions of activity but
do not confirm that the N-terminus is solely required for activity in vivo. Further
peptides will have to be created to elucidate the areas attributed to the effect. Regarding
chemotaxis, the Dips do not display migratory properties against the HEK293 cells
expressing CCR6 thus the antimicrobial and chemoattractant properties can be
separated. This provides further validation that the /3-defensins can provide a scaffold




1. Since Defrl is a variant allele of Defb8 it would be of interest to synthesise
Defb8 and study the antimicrobial profile and its ability to perform under
reduced conditions.
2. Furthermore studies of the chemoattractant properties of Defb8 would be
advantageous and interesting to confirm if this peptide uses the same
unknown receptor as that ofDefrl or a different receptor.
3. Relating to dimeric structure being important for antimicrobial activity with
Defrl, 5YC and Defrl leys, the analysis of a monomelic preparation of
Defrl leys would have great interest particularly in the area of chemotaxis.
Defbl4
4. It is unclear from the studies conducted in this thesis what the additional
receptor(s) Defbl4 utilises in order to chemoattract monocytes. Identification
of this receptor would be helpful in understanding its role within the immune
system particularly if this is the same additional receptor used by HBD3.
5. Chemotaxis was not observed with the defensin inspired peptides nor with
Defbl4 without any cysteine residues. Ideally forcing Dip3 to make a dimer
would be interesting to confirm if structural aspects are required for
interaction with CCR6.
6. Creating Defbl4 leys with biotin attached would provide a useful tool to fish
out the receptor and for membrane acting studies. Analysis of bioactivity
would have to be conducted first.
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7. Further mutations in the sequence of the N-terminus of the defensin inspired
peptides could potentially reveal the important residues required for
antimicrobial action.
8. Changing the sequence to incorporate residues important for salt resistance,
increasing potency and reducing toxicity would contribute to the drug
development process.
9. Developing a murine knockout of the jS-defensin cluster would be beneficial
in determining the defensin functions in vivo. Using the Lox P Cre
recombinase system the cluster could be removed although defensins are
present at other loci and may compensate for this initial loss.
10. Perhaps a more elegant system would be firstly to identify the enzyme
required for processing the /3-defensin and inactivate this, like the matrilysin
studies for the odefensins. This strategy would inactivate the defensin
genes.
11. Isolating Defbl4 and Defrl from their natural sources rather than analysing
the synthetic peptides would confirm if the disulfide connectivities are mixed
or if the peptides retain the native /3-defensin conformation.
12. Co-crystalise CCR6 and a /3-defensin would demonstrate the exact residues
and bonds that interact. Removing these from the peptide could potentially
allow chemotaxis to be removed.
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